<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1109234174
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Acalabrutinib BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Acalabrutinib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13972.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Natco Pharma Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Natco Pharma Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Acalabrutinib is a medicine used to treat cancer.</strong></p><p style="margin-left:40px">Acalabrutinib contains the active substance acalabrutinib.</p><p style="margin-left:40px">It belongs to a group of medicines called Bruton tyrosine kinase (BTK) inhibitors.</p><p style="margin-left:40px">&nbsp;</p><p><strong>What Acalabrutinib is used for</strong></p><p style="margin-left:40px">Acalabrutinib is used to treat adults with chronic lymphocytic leukaemia (CLL).</p><p style="margin-left:40px">CLL is a cancer of white blood cells called B-lymphocytes (or B-cells). These cells are part of the immune system (the body&rsquo;s defences).</p><p style="margin-left:80px">&nbsp;</p><p><strong>How Acalabrutinib works</strong></p><p style="margin-left:40px">Acalabrutinib works by blocking BTK, a protein in the body that helps these cancer cells grow and survive. By blocking BTK, Acalabrutinib helps to kill and can reduce the number of cancer cells which can slow down the worsening of the disease.</p><p style="margin-left:40px">If you have any questions about how Acalabrutinib works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.</p><p style="margin-left:40px">&nbsp;</p><p style="margin-left:40px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Acalabrutinib if:</strong></p><p style="margin-left:40px">you are allergic to acalabrutinib or any of the other ingredients of this medicine (listed in section 6).</p><p style="margin-left:40px">If you are not sure, talk to your doctor, pharmacist or nurse before taking Acalabrutinib capsule.</p><p style="margin-left:40px">&nbsp;</p><p><strong>Warnings and precautions</strong></p><p style="margin-left:40px">Talk to your doctor, pharmacist or nurse before taking Acalabrutinib if you:</p><ul><li>have ever had unusual bruising or bleeding or are on any medicines that increase your risk of bleeding (see section 4 &lsquo;Possible side effects&rsquo;).</li><li>have an infection (see section 4 &ldquo;Possible side effects&rsquo;)</li><li>have recently had an operation or are about to have one. Your doctor may stop treatment with Acalabrutinib before and after a medical, surgical or dental procedure.</li><li>have ever had hepatitis B (a liver infection) &ndash; this is because Acalabrutinib could cause hepatitis B to become active again and so that your doctor will look out for signs of this infection coming back (see section 4 &lsquo;Possible side effects&rsquo;).</li><li>have or ever had irregular heartbeat (see section 4 &lsquo;Possible side effects&rsquo;).</li></ul><p style="margin-left:40px">Talk to your doctor if you develop a new lesion or any change in the appearance of an area on the skin as you are at a high risk of developing skin cancer, see section 4. Use sun protection and make regular skin examination.</p><p style="margin-left:40px">Your doctor will check your blood cell counts as needed during treatment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p style="margin-left:40px">Do not give this medicine to children or adolescents aged less than 18 years. This is because it has not been studied in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Acalabrutinib</strong></p><p style="margin-left:40px">Tell your doctor, pharmacist or nurse if you are taking or have recently taken or might take any other medicines, especially if you take any of the following:</p><ul style="margin-left:40px"><li>antibiotics for bacterial infections &ndash; such as clarithromycin</li><li>medicines for fungal infections &ndash; such as posaconazole, itraconazole, voriconazole</li><li>ketoconazole &ndash; a medicine for Cushing&rsquo;s syndrome (a condition in which the body produces too much of the hormone cortisol)</li><li>medicines for HIV infections &ndash; such as indinavir and ritonavir</li><li>medicines for hepatitis C &ndash; such as telaprevir</li><li>rifampicin &ndash; an antibiotic for bacterial infections (Tuberculosis)</li><li>medicine for migraines &ndash; ergotamine</li><li>medicine for low blood sodium &ndash; conivaptan</li><li>medicine for high blood sugars &ndash; metformin</li><li>medicine to prevent organ rejection &ndash; cyclosporine</li><li>medicines for fits (seizures) or epilepsy &ndash; such as carbamazepine and phenytoin</li><li>pimozide &ndash; a medicine used for Tourette (condition which causes uncontrolled movements and outbursts of words and sounds)</li><li>St. John&rsquo;s wort &ndash; a herbal medicine for depression</li><li>theophylline &ndash; medicine used for wheezing, shortness of breath, and chest tightness</li><li>medicines for reducing Stomach acid:<ul><li>antacids &ndash; such as calcium carbonate<ul><li>Take Acalabrutinib 2 hours before or 2 hours after you take these medicines</li></ul></li><li>histamine-2 receptor blockers &ndash; such as ranitidine and famotidine<ul><li>Take Acalabrutinib 2 hours before or 10 hours after you take these medicines</li></ul></li><li>proton pump inhibitors &ndash; such as omeprazole<ul><li>Avoid taking these medicines while you are taking Acalabrutinib</li></ul></li></ul></li><li>methotrexate &ndash; a medicine for diseases such as rheumatoid arthritis, psoriasis and ulcerative colitis, which are caused by the immune system working incorrectly.<ul><li>This medicine should be taken at least 6 hours before or after Acalabrutinib.</li></ul></li></ul><p>&nbsp;</p><p><strong>Medicines that increase your risk of bleeding</strong></p><p style="margin-left:40px">Acalabrutinib may make you bleed more easily. Tell your doctor, pharmacist, or nurse if you take other medicines that increase your risk of bleeding:</p><ul><li>Antiplatelets (medicines that act against blot clotting) such as acetylsalicylic acid and clopidogrel.</li><li>Anticoagulants (blood thinners) such as warfarin or enoxaparin.</li></ul><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p style="margin-left:40px">Talk to your doctor before taking Acalabrutinib if you are pregnant, think you may be pregnant, or are planning on having a baby. This is because Acalabrutinib may harm your unborn baby.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p style="margin-left:40px">Do not breast-feed during treatment with Acalabrutinib and for 2 days after your last dose of Acalabrutinib.</p><p style="margin-left:40px">It is not known if Acalabrutinib passes into your breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p style="margin-left:40px">Acalabrutinib is unlikely to affect the ability to drive and use machines. However, if you feel dizzy, weak or tired while taking Acalabrutinib, you must not drive or use machines.</p><p>&nbsp;</p><p><strong>Acalabrutinib contains sodium</strong></p><p style="margin-left:40px">This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p style="margin-left:40px">&nbsp;</p><p style="margin-left:40px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Acalabrutinib will only be prescribed to you by a doctor with experience in the use of medicines for cancer. Always take Acalabrutinib exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p><strong>How much to take</strong></p><ul style="margin-left:40px"><li>The usual dose is one capsule (100 mg) twice a day. Take doses about 12 hours apart.</li></ul><p><strong>How to take</strong></p><ul style="margin-left:40px"><li>Swallow the capsule whole with water at about the same time each day.</li><li>Do not chew, dissolve or open the capsules as this may change how quickly the medicine gets into your body.</li><li>You can take Acalabrutinib with food or between meals.</li><li>You can check when you last took a capsule of Acalabrutinib by looking on the blister. Pictures on the blister will help you to take your dose at the right time &mdash; the sun for the morning dose and the moon for the evening dose.</li></ul><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><u>Serious side effects </u></strong></p><p>The most serious side effects of busulfan therapy or the transplant procedure may include decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion), infection, liver disorders including blocking of a liver vein, graft versus host disease (the graft attacks your body) and pulmonary complications. Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.</p><p>&nbsp;</p><p><strong><u>Other side effects may include </u></strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><ul style="margin-left:40px"><li><strong>Blood:</strong> decrease of blood circulating cells (red and white) and platelets.</li><li><strong>Infections. </strong></li><li><strong>Nervous system:</strong> insomnia, anxiety, dizziness, and depression.</li><li><strong>Nutrition:</strong> loss of appetite, decrease in magnesium, calcium, potassium, phosphate, albumine in blood, and increase in blood sugar.</li><li><strong>Cardiac:</strong> increase in heart rate, increase or decrease of blood pressure, vasodilatation (a state of increased calibre of the blood vessels), and blood clots.</li><li><strong>Respiratory:</strong> shortness of breath, nasal secretion (rhinitis), sore throat, cough, hiccup, nosebleeds, abnormal breath sounds.</li><li><strong>Gastro-intestinal:</strong> nausea, inflammation of the mucosa of the mouth, vomiting, abdominal pain, diarrhoea, constipation, heart burn, anus discomfort, liquid in the abdomen.</li><li><strong>Hepatic:</strong> enlarged liver, jaundice, blocking of a liver vein.</li><li><strong>Skin:</strong> rash, itching, loss of hairs.</li><li><strong>Muscle and bone:</strong> back, muscle and joint pain.</li><li><strong>Renal:</strong> increase in creatinine elimination, discomfort in urination, decrease in urine output and bloody urine.</li><li><strong>General:</strong> fever, headache, weakness, chills, pain, allergic reaction, oedema, general pain or inflammation at injection site, chest pain, inflammation of the mucosa.</li><li><strong>Investigations:</strong> elevated liver enzymes and weight increased.</li></ul><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><ul style="margin-left:40px"><li><strong>Nervous system:</strong> confusion, nervous system disorders.</li><li><strong>Nutrition:</strong> low blood sodium.</li><li><strong>Cardiac:</strong> changes and abnormalities in heart rhythm, fluid retention or inflammation around the heart, decrease heart output.</li><li><strong>Respiratory:</strong> increase in breath rhythm, respiratory failure, alveolar haemorrhages, asthma, collapse of small portions of the lung, fluid around the lung.</li><li><strong>Gastro-intestinal:</strong> inflammation of the mucosa of oesophagus, paralysis of the gut, vomiting blood.</li><li><strong>Skin:</strong> Skin colour disorder, redness of the skin, skin desquamation.</li><li><strong>Renal:</strong> increase in the amount of nitrogen components in the blood stream, moderate renal insufficiency, renal disorder.</li></ul><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul style="margin-left:40px"><li><strong>Nervous system:</strong> delirium, nervousness, hallucination, agitation, abnormal brain function, cerebral haemorrhage, and seizure.</li><li><strong>Cardiac:</strong> clotting of femoral artery, extra heart beats, decrease in heart rate, diffuse leak of fluid from the capillaries (small blood vessels).</li><li><strong>Respiratory:</strong> decrease in blood oxygen.</li><li><strong>Gastro-intestinal:</strong> bleeding in the stomach and/or the gut.</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Sex glands dysfunction.</li><li>Lens disorders including clouding of the lens of the eye (cataract), and blurred vision (corneal thinning).</li><li>Menopausal symptoms and female infertility.</li><li>Brain abscess, Inflammation of the skin, generalized infection.</li><li>Liver disorders.</li><li>Increase of lactate dehydrogenase in the blood.</li><li>Increase of uric acid and urea in the blood.</li><li>Incomplete development of teeth.</li></ul><p style="margin-left:40px">&nbsp;</p><p style="margin-left:40px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the vial label and carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month. &nbsp;</p><p><strong>Unopened vials:</strong></p><ul><li>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</li></ul><p style="margin-left:40px">&nbsp;</p><p><strong>Diluted solution</strong></p><ul><li>Busulfan BOS diluted in 0.9% sodium chloride injection or 5% dextrose injection is stable at room temperature (25&deg;C) for up to 8 hours but the infusion must be completed within that time. Busulfan BOS diluted in 0.9% sodium chloride injection is stable at refrigerated conditions (2&deg;‑8&deg;C) for up to 12 hours but the infusion must be completed within that time.</li><li>Do not freeze the solution.</li><li>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use. These measures will help protect the environment.</li></ul><p style="margin-left:40px">&nbsp;</p><p style="margin-left:40px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is busulfan. Each ml of solution for injection contains 6 mg busulfan.</li><li>The other ingredients are dimethylacetamide and polyethylene glycol 400.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Busulfan BOS is a clear and colourless solution for injection in a 10 mL USP Type I clear glass vial with 13 mm bromo butyl rubber stopper and aluminium flip-off seal. 
Busulfan BOS is supplied in one pack containing 8 vials.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>MAH and Secondary packaging:</u></strong></p><p>Boston Oncology Arabia Limited</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p><strong><u>Full Manufacturing and Primary Packaging:</u></strong></p><p>Gland Pharma Limited</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p><strong><em>Saudi Arabia:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>The National Pharmacovigilance Centre (NPC)</li><li>SFDA Call Centre: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Other GCC States:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li>Please contact the relevant competent authority.</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council of Arab Health Ministers</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p></td></tr><tr><td style="vertical-align:top"><ul><li>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</li><li>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</li><li>The doctor and the pharmacist are the experts in medicines, their benefits and risks.</li><li>Do not by yourself interrupt the period of treatment prescribed for you.</li><li>Do not repeat the same prescription without consulting your doctor.</li><li>Keep all medicaments out of reach of children.</li></ul></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو<strong> </strong>أكالابروتينيب بي او اس</strong></p><p dir="RTL">أكالابروتينيب بي او اس هو دواء يستخدم لعلاج السرطان.</p><ul dir="rtl"><li>يحتوي أكالابروتينيب بي او اس على المادة الفعالة أكالابروتينيب.</li><li>وهي تنتمي لمجموعة من الأدوية تُدعى بمثبطات بروتون تيروزين كيناز (BTK).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو</strong><strong> </strong><strong>استخدام أكالابروتينيب بي او اس</strong></p><p dir="RTL">يستخدم أكالابروتينيب بي او اس لعلاج المرضى البالغين المصابين بسرطان الدم اللمفاوي المزمن (CLL).</p><p dir="RTL">سرطان الدم اللمفاوي المزمن هو سرطان يصيب خلايا الدم البيضاء التي تُدعى باللمفاويات البائية (أو B-cells). وتشكل تلك الخلايا أحد أجزاء الجهاز المناعي (دفاعات الجسم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل</strong><strong> </strong><strong>أكالابروتينيب بي او اس</strong></p><p dir="RTL">يعمل أكالابروتينيب بي او اس عن طريق حصر بروتون تيروزين كيناز BTK، وهو بروتين في الجسم يساعد الخلايا السرطانية على النمو والبقاء على قيد الحياة. يساعد منع أكالابروتينيب بي او اس لـ BTKفي القضاء على الخلايا السرطانية وتقليل أعدادها، وذلك يمكن أن يبطئ من تفاقم المرض.</p><p dir="RTL">اسأل طبيبك أو الصيدلي أو الممرض إذا كان لديك أيّة أسئلة حول آلية عمل أكالابروتينيب بي او اس أو سبب وصف هذا الدواء لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم أكالابروتينيب بي او اس </strong></p><p dir="RTL"><strong>إذا كنت تتحسس</strong> من أكالابروتينيب أو أي من المكونات الأخرى لهذا الدواء (المدونة في القسم 6).</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول كبسولات أكالابروتينيب بي او اس إذا لم تكن متأكداً حول ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول أكالابروتينيب بي او اس:</p><ul dir="rtl"><li>إذا كان قد حصل لديك من قبل كدمات غير اعتيادية أو نزيف أو كنت تستخدم أي أدوية تزيد من خطر النزيف (انظر القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li><li>إذا كان لديك عدوى (انظر القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li><li>إذا أُجريت لك عملية حديثاً أو كنت على وشك ذلك. ربما يقوم طبيبك بإيقاف العلاج بمستحضر أكالابروتينيب بي او اس قبل وبعد الإجراء الطبي أو الجراحي أو السنّي.</li><li>إذا كنت قد أُصبت سابقاً بالتهاب الكبد B (عدوى في الكبد) &ndash; وذلك لأن أكالابروتينيب بي او اس يمكن أن يسبب تنشيط التهاب الكبد B، وبالتالي سيقوم طبيبك بالبحث عن علامات عودة هذه العدوى(انظر القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li><li>إذا كان لديك اضطرابات في دقات القلب أو حصل ذلك مسبقاً (انظر القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li></ul><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك إذا تطورت لديك آفة جديدة أو عند حصول أي تغير في مظهر منطقة من الجلد حيث أنك معرض لخطر كبير للإصابة بسرطان الجلد، انظر القسم 4. استخدم واقياً شمسياً وافحص جلدك بانتظام.</p><p dir="RTL">سيتحقق طبيبك من عدد خلايا الدم حسب الحاجة أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال أو المراهقين الذين يبلغون من العمر أقل من 18 عام، لأن هذا الدواء لم يُدرس على هذه الفئة العمرية. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأكالابروتينيب بي او اس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرض عن أي أدوية تتناولها أو الأدوية التي تناولتها مؤخراً أو أي أدوية أخرى ربما تكون تناولتها، وخصوصاً إذا تناولت أي من الأدوية التالية:</p><ul dir="rtl"><li>المضادات الحيوية للالتهابات البكتيرية &ndash; مثل كلاريثرومايسين</li><li>أدوية الالتهابات الفطرية &ndash; مثل بوساكونازول، إيتراكونازول، فوريكونازول</li><li>كيتوكونازول &ndash; وهو دواء يستخدم لعلاج متلازمة كوشينغ (وهي حالة يحدث فيها زيادة كبيرة في إنتاج الجسم من هرمون الكورتيزول)</li><li>أدوية عدوى فيروس نقص المناعة البشرية &ndash; مثل إيندينافير وريتونافير</li><li>الأدوية المستخدمة في علاج التهاب الكبد C &ndash; مثل تيلابريفير</li><li>ريفامبيسين &ndash;مضاد حيوي لعلاج الالتهابات البكتيرية (السل)</li><li>أدوية الشقيقة &ndash; إيرغوتامين</li><li>أدوية انخفاض صوديوم الدم &ndash; كونيفابتان</li><li>أدوية ارتفاع سكر الدم &ndash; ميتفورمين</li><li>الأدوية المستخدمة لمنع رفض الأعضاء &ndash; سيكلوسبورين</li><li>أدوية النوبات أو الصرع &ndash; مثل كاربامازيبين وفينيتوئين</li><li>بيموزيد &ndash; وهو دواء يستخدم في علاج داء توريت (حالة تتسبب بحركات تكرارية وأصوات لا يمكن السيطرة عليها بسهولة )</li><li>عشبة القديس جون &ndash; وهو دواء عشبي لعلاج الاكتئاب</li><li>ثيوفيللين &ndash; وهو دواء يستخدم لعلاج الصفير وضيق التنفس</li><li>الأدوية المستخدمة لتقليل حموضة المعدة:</li><li>&nbsp; &nbsp; &nbsp; مضادات الحموضة &ndash; مثل كربونات الكالسيوم</li><li>تناول أكالابروتينيب بي او اس قبل أو بعد ساعتين من تناول تلك الأدوية</li><li>&nbsp; &nbsp; &nbsp; &nbsp;حاصرات مستقبلات الهيستامين-2 &ndash; مثل رانيتيدين وفاموتيدين</li><li>&nbsp;تناول أكالابروتينيب بي او اس قبل ساعتين أو بعد 10 ساعات من تناول تلك الأدوية</li><li>&nbsp; &nbsp; &nbsp; &nbsp; مثبطات قنوات البروتون &ndash; مثل أوميبرازول</li><li>تجنب تناول تلك الأدوية أثناء تناول أكالابروتينيب بي او اس</li><li>ميثوتريكسات &ndash; دواء لأمراض مثل التهاب المفاصل الروماتويدي والصدفية والتهاب القولون التقرحي، وهي أمراض تحصل بسبب خلل في عمل جهاز المناعة</li><li>&nbsp; &nbsp; &nbsp; &nbsp; ينبغي تناول تلك الأدوية قبل أو بعد تناول أكالابروتينيب بي او اس بنحو 6 ساعات على الأقل</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التي تزيد خطر حدوث النزيف </strong></p><p dir="RTL">ربما يجعلك مستحضر أكالابروتينيب بي او اس تنزف بسهولة أكبر. أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول أدوية أخرى تزيد من خطر حدوث النزيف لديك:</p><ul dir="rtl"><li>مضادات الصفيحات (هي أدوية تعمل ضد تخثر الدم) مثل حمض أسيتيل سالسيسيليك وكلوبيدوغريل</li><li>مضادات التخثر (مسيلات الدم) مثل وارفارين أو إينوكسابارين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">أخبري طبيبكِ قبل تناول مستحضر أكالابروتينيب بي او اس إذا كنتِ حاملاً أو تعتقدين بأنك قد تكونين حاملاً أو تخططين للحمل. وذلك لأن أكالابروتينيب بي او اس ربما يسبب الضرر بالجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة</strong></p><p dir="RTL">لا ترضعي أثناء العلاج بمستحضر أكالابروتينيب بي او اس وحتى مرور يومين بعد آخر جرعة من أكالابروتينيب بي او اس.</p><p dir="RTL">من غير المعلوم إذا ما كان أكالابروتينيب بي او اس يصل إلى حليب الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">من غير المحتمل أن يؤثر أكالابروتينيب بي او اس في القدرة على القيادة واستخدام الآلات. لكن إذا شعرت بالدوار أو التعب أو الضعف عند تناول أكالابروتينيب بي او اس يتوجب عليك عدم القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أكالابروتينيب بي او اس يحتوي على الصوديوم </strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ميلي مول من الصوديوم (23 ملغ) لكل جرعة، وهذا يعني أنه خالٍ عملياً من الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُصرف لك دواء أكالابروتينيب بي او اس فقط من قبل طبيب خبير باستخدام الأدوية المضادة للسرطان. تناول دواء أكالابروتينيب بي او اس دائماً كما أخبرك طبيبك بالضبط. راجع الأمر مع طبيبك أو الصيدلي أو الممرض إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كم الجرعة التي عليك تناولها </strong></p><p style="margin-right:40px">الجرعة الاعتيادية هي كبسولة واحدة (100 ملغ) مرتين باليوم. تناول الجرعات بفاصل زمني 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تتناولها </strong></p><p style="margin-right:40px">ابلع الكبسولة كاملةً مع الماء في نفس التوقيت من كل يوم.</p><p style="margin-right:40px">لا تقم بمضغ أو إذابة أو فتح الكبسولة لأن ذلك ربما يغير من سرعة وصول الدواء للجسم.</p><p style="margin-right:40px">يمكنك تناول مستحضر أكالابروتينيب بي او اس مع الطعام أو بين الوجبات.</p><p dir="RTL" style="margin-right:40px">&nbsp;</p><p dir="RTL"><strong>إذا تناولت من أكالابروتينيب بي او اس أكثر مما يجب</strong></p><p dir="RTL" style="margin-right:40px">قم بزيارة طبيب أو توجه لأقرب مستشفى حالاً إذا تناولت من مستحضر أكالابروتينيب بي او اس أكثر مما ينبغي. احرص على أن تأخذ معك الكبسولات وهذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أحد الجرعات</strong></p><p style="margin-right:40px">تناول الجرعة الفائتة فوراً إذا مر على موعد تناولها المعتاد أقل من 3 ساعات. خذ الجرعة التالية في وقتك المعتاد.</p><p style="margin-right:40px">تجاوز الجرعة الفائتة إذا مر على موعد تناولها المعتاد أكثر من 3 ساعات. تناول الجرعة التالية في موعدها المعتاد.</p><p style="margin-right:40px">لا تتناول جرعة مضاعفة من أكالابروتينيب بي او اس لتعوض الجرعة الفائتة.</p><p dir="RTL" style="margin-right:40px">اسأل طبيبك أو الصيدلي أو الممرض إذا كانت لديك أيّة أسئلة إضافية حول استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن لهذا الدواء أن يسبب أعراضًا جانبية كما هو الحال بالنسبة لجميع الأدوية، لكن هذه التأثيرات لا تحدث عند جميع الأشخاص الذين يتلقونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول مستحضر أكالابروتينيب بي او اس وتواصل مع طبيب أو توجه لأقرب قسم إسعاف على الفور إذا عانيت من أحد الأعراض التالية: </strong></p><ul dir="rtl"><li>النزيف. ربما تكون الأعراض عبارة عن براز أسود أو ظهور دم في البراز، تلون البول بالبني أو الزهري، الرعاف، الكدمات، النزيف غير المتوقع، قيء أو سعال مصحوب مع الدم، الدوار، الضعف، الارتباك.</li><li>الالتهابات. ربما تشمل العلامات الحمّى، القشعريرة، الضعف أو الارتباك، السعال، ضيق في التنفس ]التهاب الرئة ، وهو <strong>تأثير جانبي شائع جداً</strong> (ربما يؤثر على أكثر من شخص واحد من كل 10 أشخاص) أو عدوى الرشاشيات، وهو <strong>تأثير جانبي غير شائع</strong> (ربما يؤثر على شخص واحد من كل 100 شخص).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية خطيرة شائعة </strong>(ربما تؤثر على شخص واحد من كل 10 أشخاص)</p><ul dir="rtl"><li>تسارع ضربات القلب، دقات قلب فائتة، دقات قلب ضعيفة أو متفاوتة، الدوار، الإغماء، انزعاج في الصدر أو ضيق التنفس (وهي علامات لاضطرابات نظم القلب تُعرف بالرجفان الأذيني والرفرفة الأذينية). &nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية خطيرة غير شائعة </strong>(ربما تؤثر على شخص واحد من كل 100 شخص)</p><ul dir="rtl"><li>الحمّى، القشعريرة، الغثيان، القيء، الارتباك، ضيق التنفس، نوبات الصرع، ضربات قلب غير منتظمة، بول داكن اللون أو عكر، تعب غير اعتيادي، ألم في المفاصل أو العضلات. يمكن أن تكون تلك أعراضاً لمتلازمة تحلل الورم وهي حالة تحدث بسبب التحطم السريع للخلايا السرطانية.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية أخرى: </strong></p><p dir="RTL"><strong>شائعة جداً </strong>(ربما تؤثر على أكثر من شخص واحد من كل 10 أشخاص)</p><ul dir="rtl"><li>ألم في المفاصل أو العضلات</li><li>الصداع</li><li>الطفح</li><li>التعب، الضعف أو فقدان الطاقة</li><li>الغثيان، القيء، ألم في المعدة، الإمساك (قليل الحدوث أو صعوبة في إخراج البراز)، الإسهال (متكرر أو براز رخو)</li><li>انخفاض تعداد كريات الدم الحمراء، انخفاض تعداد العدلات (وهي نوع من أنواع الكريات البيضاء) أو انخفاض تعداد الخلايا التي تساعد في تخثر الدم (الصفيحات)</li><li>الدوار</li><li>الصداع، ضغط أو ثقل في العينين أو الأنف أو منطقة الخد (التهاب الجيوب الأنفية)</li><li>التهاب الحلق وسيلان الأنف (التهاب البلعوم الأنفي)</li><li>التهاب في الجهاز التنفسي العلوي</li><li>التهاب في البول (ألم أو شعور بالحرقة عند التبول)</li><li>سرطانات جديدة، متضمنةً سرطانات الجلد، ربما تحدث أثناء العلاج بمستحضر أكالابروتينيب بي او اس (انظر القسم 2 &quot; ما الذي تحتاج معرفته قبل استخدام أكالابروتينيب بي او اس&quot;)</li></ul><p>&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(ربما تؤثر على شخص واحد من كل 10 أشخاص)</p><ul dir="rtl"><li>التهاب الشعب الهوائية (لا تتطلب تدخلاً عاجلاً)</li><li>الهربس</li></ul><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(ربما تؤثر على شخص واحد من كل 100 شخص)</p><ul dir="rtl"><li>فقدان الذاكرة، اضطراب التفكير، صعوبة في المشي أو فقدان البصر &ndash; قد تكون تلك علامات لحدوث عدوى خطيرة في الدماغ (اعتلال بيضاء الدماغ عديد البؤر المتقدم)</li><li>الحمى، القشعريرة، الضعف، الارتباك، الشعور بالإعياء واصفرار الجلد أو كرة العين (اليرقان) &ndash; ربما تكون تلك علامات لتنشيط التهاب الكبد B (التهاب الكبد)</li><li>كثرة اللمفاويات (ارتفاع تعداد الخلايا اللمفاوية عن النسبة الطبيعية في الدم، وهي أحد أنواع كريات الدم البيضاء)</li></ul><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</li><li>لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على الظرف والعلبة. &nbsp;ويشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</li><li>ينبغي حفظ هذا المستحضر في درجة حرارة 30 مئوية أو أقل.</li><li>لا تتخلص من أي أدوية عن طريق مياه الصرف أو نفايات المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستُساهم تلك الإجراءات بحماية البيئة.</li></ul><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أكالابروتينيب بي او اس. تحوي كل كبسولة قاسية على 100 ملغ من مادة أكالابروتينيب.</p><p dir="RTL">باقي المكونات هي:</p><ul dir="rtl"><li>محتوى الكبسولة: مانيتول ، كروسكارميلوز الصوديوم ، ثاني أكسيد السيليكون الغروي، ستيريل فومارات الصوديوم</li><li>قشور الكبسولة: الجيلاتين، ثاني أكسيد التيتانيوم، FD &amp; C Blue 2، أكسيد الحديد الأصفر، الكحول المجفف، كحول الأيزوبروبيل، كحول البوتيل، البروبيلين جليكول، محلول الأمونيا القوي، أكسيد الحديد الأسود، هيدروكسيد البوتاسيوم.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات أكالابروتينيب بي او اس هي كبسولات جيلاتينية صلبة مقاس &quot;1&quot; بلون أزرق غامق عاتم للغطاء ولون أصفر غامق عاتم للجسم، مطبوع &ldquo;NAT 100 mg&rdquo; على جسم الكبسولة بحبر أسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأتي كبسولات أكالابروتينيب بي او اس في أشرطة من 60 كبسولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق والشركة المصنّعة</strong></p><p dir="RTL"><strong><u>مالك حقوق التسويق والتغليف الثانوي:</u></strong></p><p dir="RTL">شركة بوستن اونكولوجي العربية المحدودة</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>التصنيع الكامل والتغليف الأولي:</u></strong></p><p dir="RTL">ناتكو فارما المحدودة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لإبلاغنا عن أي تأثيرات جانبية عبر:</strong></p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:539px"><tbody><tr><td style="vertical-align:top"><ul dir="rtl"><li>المركز الوطني للتيقظ الدوائي <strong>The National Pharmacovigilance Centre (NPC)</strong></li><li>رقم هيئة الغذاء والدواء السعودية: 19999</li><li>البريد الإلكتروني: &nbsp;npc.drug@sfda.gov.sa</li><li>موقع الشبكة: &nbsp;https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي </strong><strong>الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul dir="rtl"><li>الرجاء التواصل مع الجهات المختصة في كل دولة.</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مجلس وزراء الصحة العرب</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL" style="text-align:center"><strong>هذا الدواء</strong></p><ul dir="rtl"><li>هو مستحضر يُؤثر على صحتك، واستهلاكه خلافاً للتعليمات يعرضك للخطر.</li><li>اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</li><li>الطبيب والصيدلي هم الخبيران في منافع الأدوية ومضارّها.</li><li>لا توقف الدواء من تلقاء نفسك قبل انتهاء مدة العلاج الموصوفة لك.</li><li>لا تكرر صرف الدواء دون استشارة الطبيب المختصّ.</li><li>لا تترك الأدوية في متناول الأطفال.</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             09/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acalabrutinib BOS
Acalabrutinib BOS Capsules 100mg




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains
Acalabrutinib dihydrate is equivalent to 100 mg of Acalabrutinib.

For the full list of excipients, see section 6.1.





            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule).
Hard gelatine capsules size ‘1’ with dark blue opaque color cap and yellow opaque body and printed. 
with “NAT 100 mg” on body in black ink





            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic Indications Acalabrutinib as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).</p><p>Acalabrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with this medicinal product should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p>&nbsp;</p><p><strong><u>Posology</u></strong></p><p>The recommended dose is 100 mg Acalabrutinib twice daily (equivalent to a total daily dose of 200 mg). Refer to obinutuzumab prescribing information for recommended Obinutuzumab dosing information.</p><p>The dose interval is approximately 12 hours.</p><p>Treatment with Acalabrutinib should be continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><strong><u>Dose adjustments</u></strong></p><p><em>Adverse reactions</em></p><p>Recommended dose modifications of Acalabrutinib for Grade &ge; 3 adverse reactions are provided in Table 1</p><p>Table 1. Recommended dose adjustments for adverse reactions*</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction occurrence</strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p><p><strong>(Starting dose = 100mg approximately every 12 hours)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p><p>thrombocytopenia with</p><p>bleeding,</p><p>Grade 4</p></td><td style="vertical-align:top"><p>First and</p><p>second</p></td><td style="vertical-align:top"><p>Interrupt Acalabrutinib</p><p>Once toxicity has resolved to</p><p>Grade 1 or baseline,</p><p>Acalabrutinib may be resumed at 100mg approximately every 12 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>thrombocytopenia or Grade 4 neutropenia lasting longer than 7 days.</p><p>&nbsp;</p><p>Grade 3 or greater nonhematological toxicities</p></td><td style="vertical-align:top"><p>Third</p></td><td style="vertical-align:top"><p>Interrupt Acalabrutinib Once toxicity has resolved to Grade 1</p><p>or baseline, Acalabrutinib may</p><p>be resumed at a reduced frequency of 100mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Fourth</p></td><td style="vertical-align:top"><p>Discontinue Acalabrutinib</p></td></tr></tbody></table><p>*Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events</p><p>&nbsp;</p><p>&nbsp;</p><p>Interactions Recommendations regarding use of Acalabrutinib with CYP3A inhibitors or inducers and gastric acid reducing agents are provided in Table 2 (see section 4.5).</p><p>Table 2. Use with CYP3A inhibitors or inducers and gastric acid reducing agents</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Co-administered medicinal product</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Acalabrutinib use</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>CYP3A</strong></p><p><strong>inhibitors</strong></p></td><td style="vertical-align:top"><p>Strong CYP3A inhibitor</p></td><td style="vertical-align:top"><p>Avoid concomitant use.</p><p>If these inhibitors will be used short-term (such as anti-infectives for up to seven days), interrupt Acalabrutinib</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP3A inhibitor</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor patients closely for adverse reactions if taking moderate CYP3A inhibitors</p></td></tr><tr><td style="vertical-align:top"><p>Mild CYP3A inhibitor</p></td><td style="vertical-align:top"><p>No dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p><strong>CYP3A</strong></p><p><strong>inducers</strong></p></td><td style="vertical-align:top"><p>Strong CYP3A inducer</p></td><td style="vertical-align:top"><p>Avoid concomitant use.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Gastric acid reducing agents</strong></p></td><td style="vertical-align:top"><p>Proton pump inhibitors</p></td><td style="vertical-align:top"><p>Avoid concomitant use.</p></td></tr><tr><td style="vertical-align:top"><p>H2-receptor antagonists</p></td><td style="vertical-align:top"><p>Take Acalabrutinib 2 hours before (or 10 hours after) taking a H2-receptor antagonist.</p></td></tr><tr><td style="vertical-align:top"><p>Antacids</p></td><td style="vertical-align:top"><p>The interval between taking the medicinal products should be at least 2 hours.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u><strong>Missed dose</strong></u></p><p>If a patient misses a dose of Acalabrutinib by more than 3 hours, the patient should be instructed to take the next dose at its regularly scheduled time. Double dose of Acalabrutinib should not be taken to make up for a missed dose.</p><p>&nbsp;</p><p><strong><u>Special populations </u></strong></p><p><em>Elderly</em></p><p>No dose adjustment is required for elderly patients (aged &ge; 65 years) (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>No specific clinical studies have been conducted in patients with renal impairment. Patients with mild or moderate renal impairment were treated in Acalabrutinib clinical studies. No dose adjustment is needed for patients with mild or moderate renal impairment (greater than 30 mL/min creatinine clearance). Hydration should be maintained, and serum creatinine levels monitored periodically Acalabrutinib should be administered to patients with severe renal impairment (&lt; 30mL/min creatinine&nbsp;clearance) only if the benefit outweighs the risk and these patients should be monitored closely for signs of toxicity. There are no data in patients with severe renal impairment or patients on dialysis (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>No dose adjustment is recommended in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B, or total bilirubin between 1.5-3 times the upper limit of normal [ULN] and any AST). However, patients with moderate hepatic impairment should be closely monitored for signs of toxicity. It is not recommended to use Acalabrutinib in patients with severe hepatic impairment (Child-Pugh C or total bilirubin &gt;3 times ULN and any AST) (see section 5.2).</p><p>&nbsp;</p><p><em>Severe cardiac disease </em></p><p>Patients with severe cardiovascular disease were excluded from Acalabrutinib clinical studies. Paediatric population The safety and efficacy of Acalabrutinib in children and adolescents aged 0 to 18 years have not been established. No data are available.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Acalabrutinib is for oral use. The capsules should be swallowed whole with water at approximately the same time each day, with or without food (see section 4.5). The capsulesshould not be chewed, dissolved or opened as this may affect the absorption of the medicinal product into the body.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Haemorrhage</strong></u></p><p>Major haemorrhagic events including central nervous system and gastrointestinal haemorrhage, some with fatal outcome, have occurred in patients with haematologic malignancies treated with Acalabrutinib monotherapy and in combination with obinutuzumab. These events have occurred in patients both with and without thrombocytopenia. Overall, the bleeding events were less severe events including bruising and petechiae (see section 4.8).</p><p>The mechanism for the bleeding events is not well understood. Patients receiving antithrombotic agents may be at increased risk of haemorrhage. Use caution with antithrombotic agents and consider additional monitoring for signs of bleeding when concomitant use is medically necessary. Warfarin or other vitamin K antagonists should not be administered concomitantly with Acalabrutinib. Consider the benefit-risk of withholding Acalabrutinib for at least 3 days pre- and post-surgery.</p><p>&nbsp;</p><p><u><strong>Infections</strong></u></p><p>Serious infections (bacterial, viral or fungal), including fatal events have occurred in patients with haematologic malignancies treated with Acalabrutinib monotherapy and in combination with obinutuzumab. These infections predominantly occurred in the absence of Grade 3 or 4 neutropenia, with neutropenic infection reported in 1.9% of all patients. Infections due to hepatitis B virus (HBV) and herpes zoster virus (HZV) reactivation, aspergillosis and progressive multifocal leukoencephalopathy (PML) have occurred (see section 4.8).</p><p>&nbsp;</p><p><u><strong>Viral reactivation </strong></u></p><p>Cases of hepatitis B reactivation have been reported in patients receiving Acalabrutinib. Hepatitis B virus (HBV) status should be established before initiating treatment with Acalabrutinib. If patients have positive hepatitis B serology, a liver disease expert should be consulted before the start of treatment, and&nbsp;the patient should be monitored and managed following local medical standards to prevent hepatitis B reactivation.</p><p>&nbsp;</p><p>Cases of progressive multifocal leukoencephalopathy (PML) including fatal ones have been reported following the use of Acalabrutinib within the context of a prior or concomitant immunosuppressive therapy. Physicians should consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioural signs or symptoms. If PML is suspected, then appropriate diagnostic evaluations should be undertaken and treatment with Acalabrutinib should be suspended until PML is excluded. If any doubt exists, referral to a neurologist and appropriate diagnostic measures for PML including MRI scan preferably with contrast, cerebrospinal fluid (CSF) testing for JC Viral DNA and repeat neurological assessments should be considered.</p><p>&nbsp;</p><p>Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor patients for signs and symptoms of infection and treat as medically appropriate.</p><p>&nbsp;</p><p><strong><u>Cytopenias</u></strong></p><p>Treatment-emergent Grade 3 or 4 cytopenias, including neutropenia, anaemia and thrombocytopenia, occurred in patients with haematologic malignancies treated with Acalabrutinib monotherapy and in combination with obinutuzumab. Monitor complete blood counts as medically indicated (see section 4.8).</p><p>&nbsp;</p><p><u><strong>Second primary malignancies </strong></u></p><p>Second primary malignancies, including skin and non-skin cancers, occurred in patients with haematologic malignancies treated with Acalabrutinib monotherapy and in combination with obinutuzumab. Skin cancers were commonly reported. Monitor patients for the appearance of skin cancers and advise protection from sun exposure (see section 4.8).</p><p>&nbsp;</p><p><strong><u>Atrial fibrillation </u></strong></p><p>Atrial fibrillation/flutter occurred in patients with haematologic malignancies treated with Acalabrutinib monotherapy and in combination with obinutuzumab. Monitor for symptoms (e.g., palpitations, dizziness, syncope, chest pain, dyspnoea) of atrial fibrillation and atrial flutter and obtain an ECG as medically indicated (see sections 4.5 and 4.2). In patients who develop atrial fibrillation on therapy with Acalabrutinib, a thorough assessment of the risk for thromboembolic disease should be undertaken. In patients at high risk for thromboembolic disease, tightly controlled treatment with anticoagulants and alternative treatment options to Acalabrutinib should be considered.</p><p>&nbsp;</p><p><u><strong>Other medicinal products </strong></u></p><p>Co-administration of strong CYP3A inhibitors with Acalabrutinib may lead to increased acalabrutinib exposure and consequently a higher risk for toxicity. On the contrary, coadministration of CYP3A inducers may lead to decreased acalabrutinib exposure and consequently a risk for lack of efficacy. Concomitant use with strong CYP3A inhibitors should be avoided. If these inhibitors will be used shortterm (such as anti-infectives for up to seven days), treatment with Acalabrutinib should be interrupted. Patients should be closely monitored for signs of toxicity if a moderate CYP3A inhibitor is used (see sections 4.2 and 4.5). Concomitant use with strong CYP3A4 inducers should be avoided due to risk for lack of efficacy.</p><p>&nbsp;</p><p><u><strong>Acalabrutinib contains sodium </strong></u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acalabrutinib and its active metabolite are primarily metabolised by cytochrome P450 enzyme 3A4 (CYP3A4), and both substances are substrates for P-gp and breast cancer resistance protein (BCRP).</p><p>&nbsp;</p><p><u><strong>Active substances that may increase acalabrutinib plasma concentrations </strong></u></p><p>CYP3A/P-gp inhibitors</p><p>Co-administration with a strong CYP3A/P-gp inhibitor (200 mg itraconazole once daily for 5 days) increased acalabrutinib Cmax and AUC by 3.9-fold and 5.0-fold in healthy subjects (N=17), respectively.</p><p>Concomitant use with strong CYP3A/P-gp inhibitors should be avoided. If the strong CYP3A/P-gp inhibitors (e.g., ketoconazole, conivaptan, clarithromycin, indinavir, itraconazole, ritonavir, telaprevir, posaconazole, voriconazole) will be used short-term, treatment with Acalabrutinib should be interrupted (see section 4.2).</p><p>Co-administration with moderate CYP3A inhibitors (400 mg fluconazole as single dose or 200 mg isavuconazole as repeated dose for 5 days) in healthy subjects increased acalabrutinib Cmax and AUC by 1.4-fold to 2-fold while the active metabolite ACP-5862 Cmax and AUC was decreased by 0.65-fold to 0.88-fold relative to when acalabrutinib was dosed alone. No dose adjustment is required in combination with moderate CYP3A inhibitors. Monitor patients closely for adverse reactions (see Section 4.2).</p><p>&nbsp;</p><p><strong><u>Active substances that may decrease acalabrutinib plasma concentrations </u></strong></p><p>CYP3A inducers</p><p>Co-administration of a strong CYP3A inducer (600 mg rifampicin once daily for 9 days) decreased acalabrutinib Cmax and AUC by 68% and 77% in healthy subjects (N=24), respectively.</p><p>Concomitant use with strong inducers of CYP3A activity (e.g., phenytoin, rifampicin, carbamazepine) should be avoided. Concomitant treatment with St. John&#39;s wort, which may unpredictably decrease acalabrutinib plasma concentrations, should be avoided.</p><p>&nbsp;</p><p><em>Gastric acid reducing medicinal products</em></p><p>Acalabrutinib solubility decreases with increasing pH. Co-administration of acalabrutinib with an antacid (1 g calcium carbonate) decreased acalabrutinib AUC by 53% in healthy subjects. Coadministration with a proton pump inhibitor (40 mg omeprazole for 5 days) decreased acalabrutinib AUC by 43%.</p><p>&nbsp;</p><p>If treatment with an acid reducing agent is required, consider using an antacid (e.g., calcium carbonate), or an H2-receptor antagonist (e.g., ranitidine or famotidine). For use with antacids, the interval between taking the medicinal product should be at least 2 hours (see section 4.2). For H2-receptor antagonists, take Acalabrutinib should be taken 2 hours before (or 10 hours after) taking the H2-receptor antagonist.</p><p>Due to the long-lasting effect of proton pump inhibitors, separation of doses with proton pump inhibitors may not eliminate the interaction with Acalabrutinib and therefore concomitant use should be avoided (see section 4.2).</p><p>&nbsp;</p><p><strong><u>Active substances whose plasma concentrations may be altered by Acalabrutinib </u></strong></p><p>CYP3A substrates</p><p>Based on in vitro data, it cannot be excluded that acalabrutinib is an inhibitor of CYP3A4 at the intestinal level and may increase the exposure of CYP3A4 substrates sensitive to gut CYP3A metabolism. Caution should be exercised if co-administering acalabrutinib with CYP3A4 substrates with narrow therapeutic range administered orally (e.g., cyclosporine, ergotamine, pimozide).</p><p>&nbsp;</p><p><em>Effect of acalabrutinib on CYP1A2 substrates </em></p><p>In vitro studies indicate that acalabrutinib induces CYP1A2. Co-administration of acalabrutinib with CYP1A2 substrates (e.g., theophylline, caffeine) may decrease their exposure.</p><p>Effects of acalabrutinib and its active metabolite, ACP-5862, on medicinal product transport systems Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate)by inhibition of intestinal BCRP (see section 5.2). To minimise the potential for an interaction in the Gastrointestinal (GI) tract, oral narrow therapeutic range BCRP substrates such as methotrexate should be taken at least 6 hours before or after acalabrutinib.</p><p>ACP-5862 may increase exposure to co-administered MATE1 substrates (e.g., metformin) by inhibition of MATE1 (see section 5.2). Patients taking concomitant medicinal products with disposition dependent upon MATE1 (e.g., metformin) should be monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication whilst receiving Acalabrutinib.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Women of childbearing potential</strong></u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving Acalabrutinib</p><p>&nbsp;</p><p><u><strong>Pregnancy</strong></u></p><p>There are no or limited amount of data from the use of acalabrutinib in pregnant women. Based on findings from animal studies, there may be a risk to the foetus from exposure to acalabrutinib during pregnancy. Dystocia (difficult or prolonged labour) was observed in the rat and administration to pregnant rabbits was associated with reduced foetal growth (see section 5.3).</p><p>Acalabrutinib should not be used during pregnancy unless the clinical condition of the woman requires treatment with acalabrutinib.</p><p>&nbsp;</p><p><strong><u>Breast-feeding </u></strong></p><p>It is not known whether acalabrutinib is excreted in human milk. There are no data on the effect of acalabrutinib on the breast-fed child or on milk production. Acalabrutinib and its active metabolite were present in the milk of lactating rats. A risk to the breast-fed child cannot be excluded. Breast-feeding mothers are advised not to breast-feed during treatment with Acalabrutinib and for 2 days after receiving the last dose.</p><p>&nbsp;</p><p><u><strong>Fertility </strong></u></p><p>There are no data on the effect of Acalabrutinib on human fertility. In a non-clinical study of acalabrutinib in male and female rats, no adverse effects on fertility parameters were observed (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acalabrutinib has no or negligible influence on the ability to drive and use machines. However, during treatment with acalabrutinib, fatigue and dizziness have been reported and patients who experience these symptoms should be advised not to drive or use machines until symptoms abate.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>Of the 1040 patients treated with Acalabrutinib monotherapy, the most common (&ge; 20%) adverse drug reactions (ADRs) of any grade reported in patients were infection (66.7%), headache (37.8%), diarrhoea (36.7%), bruising (34.1%), musculoskeletal pain (33.1%), nausea (21.7%), fatigue (21.3%), cough (21%) and rash (20.3%). The most commonly reported (&ge; 5%) Grade &ge; 3 adverse drug reactions were&nbsp;infection (17.6%), leukopenia (14.3%), neutropenia (14.2%), and anaemia (7.8%).</p><p>&nbsp;</p><p>Of the 223 patients treated with Acalabrutinib combination therapy, the most common (&ge; 20%) ADRs of any grade reported in patients were infection (74%), musculoskeletal pain (44.8%), diarrhoea (43.9%), headache (43%), leukopenia (31.8%), neutropenia (31.8%), cough (30.5%), fatigue (30.5%), arthralgia (26.9%), nausea (26.9%), dizziness (23.8%), and constipation (20.2%). The most commonly reported (&ge; 5%) Grade &ge; 3 adverse drug reactions were leukopenia (30%), neutropenia (30%), infection (21.5%), thrombocytopenia (9%) and anaemia (5.8%).</p><p>&nbsp;</p><p><strong><u>Tabulated list of adverse reactions </u></strong></p><p>The following adverse drug reactions (ADRs) have been identified in clinical studies with patients receiving Acalabrutinib as treatment for haematological malignancies. The median duration of Acalabrutinib treatment across the pooled dataset was 26.2 months.</p><p>Adverse drug reactions are listed according to system organ class (SOC) in MedDRA. Within each system organ class, the adverse drug reactions are sorted by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each ADR is defined as: very common (&ge; 1/10); common (&gt; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness</p><p>&nbsp;</p><p>Table 3. Adverse drug reactions* of patients with haematological malignancies treated with acalabrutinib monotherapy (n=1040)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA SOC</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Term</strong></p></td><td style="vertical-align:top"><p><strong>Overall Frequency (all CTCAE grades)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of</strong></p><p><strong>CTCAE Grade &ge; 3<sup>&dagger;</sup></strong></p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Very common (22%)</p></td><td style="vertical-align:top"><p>0.8%</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>Very common (10.7%)</p></td><td style="vertical-align:top"><p>0.3%</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>Common (8.7%)</p></td><td style="vertical-align:top"><p>5.1%</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common (8.5%)</p></td><td style="vertical-align:top"><p>1.5%</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Common (7.4%)</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>Common (7.6%)</p></td><td style="vertical-align:top"><p>0.3%</p></td></tr><tr><td style="vertical-align:top"><p>Herpes viral infections<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Common (5.9%)</p></td><td style="vertical-align:top"><p>0.7%</p></td></tr><tr><td style="vertical-align:top"><p>Aspergillus infections<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Uncommon (0.5%)</p></td><td style="vertical-align:top"><p>0.4%</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis B reactivation</p></td><td style="vertical-align:top"><p>Uncommon (0.1%)</p></td><td style="vertical-align:top"><p>0.1%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Neoplasms benign, malignant and unspecified</strong></p></td><td style="vertical-align:top"><p>Second Primary Malignancy<sup>&dagger;</sup></p><p>Non-melanoma skin malignancy<sup>&dagger;</sup></p><p>SPM excluding non- melanoma skin<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very common (12.2%)</p><p>Common (6.6%)</p><p>Common (6.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.1%</p><p>0.5%</p><p>3.8%</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Neutropenia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very common (15.7%)</p></td><td style="vertical-align:top"><p>14.2%</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very common (13.8%)</p></td><td style="vertical-align:top"><p>7.8%</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Common (8.9%)</p></td><td style="vertical-align:top"><p>4.8%</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytosis</p></td><td style="vertical-align:top"><p>Uncommon (0.3%)</p></td><td style="vertical-align:top"><p>0.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Tumour Lysis Syndrome<sup>&plusmn;</sup></p></td><td style="vertical-align:top"><p>Uncommon (0.5%)</p></td><td style="vertical-align:top"><p>0.4%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common (37.8%)</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top; width:256px"><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>&nbsp;</p></td><td style="vertical-align:top; width:210px">&nbsp;</td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Dizziness</p></td><td style="vertical-align:top; width:210px"><p>Very common (13.4%)</p></td><td style="vertical-align:top; width:110px"><p>0.2%</p></td></tr><tr><td style="vertical-align:top; width:256px"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>Atrial fibrillation/Flutter<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:210px"><p>Common (4.4%)</p></td><td style="vertical-align:top; width:110px"><p>1.3%</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:256px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>&nbsp;</p><p>Bruising<sup>&dagger;</sup> Contusion Petechiae Ecchymoses</p></td><td style="vertical-align:top; width:210px"><p>Very common (34.1%)</p><p>Very Common (21.7%)</p><p>Very Common (10.7%)</p><p>Common (6.3%)</p></td><td style="vertical-align:top; width:110px"><p>0%</p><p>0%</p><p>0%</p><p>0%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Haemorrhage/haematoma<sup>&dagger;</sup> Gastrointestinal haemorrhage</p><p>Intracranial haemorrhage</p></td><td style="vertical-align:top; width:210px"><p>Very common (12.6%)</p><p>Common (2.3%)</p><p>Common (1%)</p></td><td style="vertical-align:top; width:110px"><p>1.8%</p><p>0.6%</p><p>0.5%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Epistaxis</p></td><td style="vertical-align:top; width:210px"><p>Common (7%)</p></td><td style="vertical-align:top; width:110px"><p>0.3%</p></td></tr><tr><td rowspan="5" style="vertical-align:top; width:256px"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>Diarrhoea</p></td><td style="vertical-align:top; width:210px"><p>Very common (36.7%)</p></td><td style="vertical-align:top; width:110px"><p>2.6%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Nausea</p></td><td style="vertical-align:top; width:210px"><p>Very common (21.7%)</p></td><td style="vertical-align:top; width:110px"><p>1.2%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Constipation</p></td><td style="vertical-align:top; width:210px"><p>Very common</p><p>(14.5%)</p></td><td style="vertical-align:top; width:110px"><p>0.1%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Vomiting</p></td><td style="vertical-align:top; width:210px"><p>Very common (13.3%)</p></td><td style="vertical-align:top; width:110px"><p>0.9%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Abdominal pain<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (12.5%)</p></td><td style="vertical-align:top; width:110px"><p>1%</p></td></tr><tr><td style="vertical-align:top; width:256px"><p><strong>Skin and subcutaneous tissue</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>&nbsp;</p><p>Rash<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (20.3%)</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p><p>0.6%</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:256px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:209px"><p>Musculoskeletal Pain<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (33.1%)</p></td><td style="vertical-align:top; width:110px"><p>1.5%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Arthralgia</p></td><td style="vertical-align:top; width:210px"><p>Very common (19.1%)</p></td><td style="vertical-align:top; width:110px"><p>0.7%</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:256px"><p><strong>General disorders and administration</strong></p><p><strong>site conditions</strong></p></td><td style="vertical-align:top; width:209px"><p>Fatigue</p></td><td style="vertical-align:top; width:210px"><p>Very common</p><p>(21.3%)</p></td><td style="vertical-align:top; width:110px"><p>1.7%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Asthenia</p></td><td style="vertical-align:top; width:210px"><p>Common (5.3%)</p></td><td style="vertical-align:top; width:110px"><p>0.8%</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:256px"><p>&nbsp;</p><p><strong>Investigations</strong><sup>&para;</sup> <strong>(Findings based on test results)</strong></p></td><td style="vertical-align:top; width:209px"><p>Haemoglobin decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (42.6%)</p></td><td style="vertical-align:top; width:110px"><p>10.1%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Absolute neutrophil count decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (41.8%)</p></td><td style="vertical-align:top; width:110px"><p>20.7%</p></td></tr><tr><td style="vertical-align:top; width:209px"><p>Platelets decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:210px"><p>Very common (31.1%)</p></td><td style="vertical-align:top; width:110px"><p>6.9%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p><sup>&dagger;</sup>Includes multiple ADR term.</p><p><sup>&plusmn;</sup>One case of drug-induced Tumour Lysis Syndrome was observed in acalabrutinib arm in the ASCEND Study.</p><p>&sect;Represents the incidence of laboratory findings, not of reported adverse events.</p><p>&para; Presented as CTCAE grade values.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Table 4. Adverse drug reactions* of patients with haematological malignancies treated with acalabrutinib combination therapy (n=223)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:254px"><p><strong>MedDRA SOC</strong></p></td><td style="vertical-align:top; width:210px"><p><strong>MedDRA Term</strong></p></td><td style="vertical-align:top; width:216px"><p><strong>Overall Frequency (all CTCAE grades)</strong></p></td><td style="vertical-align:top; width:105px"><p><strong>Frequency of</strong></p><p><strong>CTCAE Grade &ge; 3<sup>&dagger;</sup></strong></p></td></tr><tr><td rowspan="10" style="vertical-align:top; width:254px"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top; width:210px"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top; width:216px"><p>Very common (31.4%)</p></td><td style="vertical-align:top; width:105px"><p>1.8%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Sinusitis</p></td><td style="vertical-align:top; width:216px"><p>Very common</p><p>(15.2%)</p></td><td style="vertical-align:top; width:105px"><p>0.4%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Nasopharyngitis</p></td><td style="vertical-align:top; width:216px"><p>Very common (13.5%)</p></td><td style="vertical-align:top; width:105px"><p>0.4%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Urinary tract infection</p></td><td style="vertical-align:top; width:216px"><p>Very common (13%)</p></td><td style="vertical-align:top; width:105px"><p>0.9%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Pneumonia</p></td><td style="vertical-align:top; width:216px"><p>Very common (10.8%)</p></td><td style="vertical-align:top; width:105px"><p>5.4%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Bronchitis</p></td><td style="vertical-align:top; width:216px"><p>Common (9.9%)</p></td><td style="vertical-align:top; width:105px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Herpes viral infections<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Common (6.7%)</p></td><td style="vertical-align:top; width:105px"><p>1.3%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Progressive multifocal leukoencephalopathy</p></td><td style="vertical-align:top; width:216px"><p>Uncommon (0.4%)</p></td><td style="vertical-align:top; width:105px"><p>0.4%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Hepatitis B reactivation</p></td><td style="vertical-align:top; width:216px"><p>Uncommon (0.9%)</p></td><td style="vertical-align:top; width:105px"><p>0.1%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Aspergillus infections<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very rare (0%)</p></td><td style="vertical-align:top; width:105px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:254px"><p><strong>&nbsp;</strong></p><p><strong>Neoplasms benign, malignant and unspecified</strong></p></td><td style="vertical-align:top; width:210px"><p>Second primary malignancy<sup>&dagger;</sup></p><p>Non-melanoma skin malignancy<sup>&dagger;</sup></p><p>SPM excluding non- melanoma skin<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (13%)</p><p>Common (7.6%)</p><p>Common (6.3%)</p></td><td style="vertical-align:top; width:105px"><p>4.0%</p><p>0.4%</p><p>3.6%</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:254px"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>Neutropenia<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (31.8%)</p></td><td style="vertical-align:top; width:105px"><p>30%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Thrombocytopenia<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common</p><p>(13.9%)</p></td><td style="vertical-align:top; width:105px"><p>9%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Anaemia<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (11.7%)</p></td><td style="vertical-align:top; width:105px"><p>5.8%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Lymphocytosis</p></td><td style="vertical-align:top; width:216px"><p>Uncommon (0.4%)</p></td><td style="vertical-align:top; width:105px"><p>0.4%</p></td></tr><tr><td style="vertical-align:top; width:254px"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>Tumour lysis syndrome<sup>&plusmn;</sup></p></td><td style="vertical-align:top; width:216px"><p>Uncommon (1.8%)</p></td><td style="vertical-align:top; width:105px"><p>1.3%</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:254px"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>Headache</p></td><td style="vertical-align:top; width:216px"><p>Very common (43%)</p></td><td style="vertical-align:top; width:105px"><p>0.9%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Dizziness</p></td><td style="vertical-align:top; width:216px"><p>Very common (23.8%)</p></td><td style="vertical-align:top; width:105px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:254px"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>Atrial fibrillation/flutter<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Common (3.1%)</p></td><td style="vertical-align:top; width:105px"><p>0.9%</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:254px"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top; width:210px"><p><strong>&nbsp;</strong></p><p>Bruising<sup>&dagger;</sup> Contusion Petechiae Ecchymoses</p></td><td style="vertical-align:top; width:216px"><p>Very common (38.6%)</p><p>Very common (27.4%)</p><p>Very common (11.2%)</p><p>Common (3.1%)</p></td><td style="vertical-align:top; width:105px"><p>0%</p><p>0%</p><p>0%</p><p>0%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Haemorrhage/haematoma<sup>&dagger;</sup> Gastrointestinal haemorrhage</p><p>Intracranial haemorrhage</p></td><td style="vertical-align:top; width:216px"><p>Very common (17.5%)</p><p>Common (3.6%)</p><p>Uncommon (0.9%)</p></td><td style="vertical-align:top; width:105px"><p>1.3%</p><p>0.9%</p><p>0%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Epistaxis</p></td><td style="vertical-align:top; width:216px"><p>Common (8.5%)</p></td><td style="vertical-align:top; width:105px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:254px"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top; width:210px"><p>Diarrhoea</p></td><td style="vertical-align:top; width:216px"><p>Very common&nbsp;(43.9%)</p></td><td style="vertical-align:top; width:105px"><p>4.5%</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:782px"><tbody><tr><td rowspan="5" style="vertical-align:top; width:254px"><p><strong>disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top; width:216px"><p>&nbsp;</p></td><td style="vertical-align:top; width:101px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Nausea</p></td><td style="vertical-align:top; width:216px"><p>Very common (26.9%)</p></td><td style="vertical-align:top; width:101px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Constipation</p></td><td style="vertical-align:top; width:216px"><p>Very common (20.2%)</p></td><td style="vertical-align:top; width:101px"><p>0%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Vomiting</p></td><td style="vertical-align:top; width:216px"><p>Very common</p><p>(19.3%)</p></td><td style="vertical-align:top; width:101px"><p>0.9%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Abdominal pain<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (14.8%)</p></td><td style="vertical-align:top; width:101px"><p>1.3%</p></td></tr><tr><td style="vertical-align:top; width:254px"><p>S<strong>kin and</strong></p><p><strong>subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top; width:210px"><p><strong>&nbsp;</strong></p><p>Rash<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (30.9%)</p></td><td style="vertical-align:top; width:101px"><p><strong>&nbsp;</strong></p><p>1.8%</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:254px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:210px"><p>Musculoskeletal pain<sup>&dagger;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (44.8%)</p></td><td style="vertical-align:top; width:101px"><p>2.2%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Arthralgia</p></td><td style="vertical-align:top; width:216px"><p>Very common (26.9%)</p></td><td style="vertical-align:top; width:101px"><p>1.3%</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:254px"><p><strong>General disorders and administration</strong></p><p><strong>site conditions</strong></p></td><td style="vertical-align:top; width:210px"><p>Fatigue</p></td><td style="vertical-align:top; width:216px"><p>Very common (30.5%)</p></td><td style="vertical-align:top; width:101px"><p>1.8%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Asthenia</p></td><td style="vertical-align:top; width:216px"><p>Common (7.6%)</p></td><td style="vertical-align:top; width:101px"><p>0.4%</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:254px"><p><strong>Investigations<sup>&para;</sup> </strong>(Findings based on test results)</p></td><td style="vertical-align:top; width:210px"><p>Absolute neutrophil count decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (57.4%)</p></td><td style="vertical-align:top; width:101px"><p>35%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Platelets decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (46.2%)</p></td><td style="vertical-align:top; width:101px"><p>10.8%</p></td></tr><tr><td style="vertical-align:top; width:210px"><p>Haemoglobin decreased<sup>&sect;</sup></p></td><td style="vertical-align:top; width:216px"><p>Very common (43.9%)</p></td><td style="vertical-align:top; width:101px"><p>9%</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:781px"><p>*Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p>&dagger;Includes multiple ADR term.</p><p>&plusmn;One case of drug-induced Tumour Lysis Syndrome was observed in the acalabrutinib arm in the ASCEND Study.</p><p>&sect;Represents the incidence of laboratory findings, not of reported adverse events.</p><p>&para; Presented as CTCAE grade values.</p></td></tr></tbody></table><p>&nbsp;</p><p><u><strong>Description of selected adverse reactions </strong></u></p><p>Discontinuation and dose reduction due to adverse reactions</p><p>Of the 1,040 patients treated with Acalabrutinib monotherapy, discontinuation due to adverse reactions were reported in 9.3% of the patients. These main adverse reactions included pneumonia, thrombocytopenia and diarrhoea. Dose reductions due to adverse reactions were reported in 4.2% of patients. These main adverse reactions included hepatitis B reactivation, sepsis, and diarrhoea.</p><p>Of the 223 patients treated with Acalabrutinib combination, discontinuation due to adverse reactions were reported in 10.8% of the patients. These main adverse reactions included pneumonia, thrombocytopenia and diarrhoea. Dose reductions due to adverse reactions were reported in 6.7% of patients. These main adverse reactions included neutropenia, diarrhoea and vomiting.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Of the 1,040 patients in clinical studies of Acalabrutinib monotherapy, 41% were greater than 65 years and less than 75 years of age and 22% were 75 years of age or older. No clinically relevant differences in safety or efficacy were observed between patients &ge; 65 years and younger. Of the 223 patients in clinical studies of Acalabrutinib in combination of obinutuzumab therapy, 47% were greater than 65 years and less than 75 years of age and 26% were 75 years of age or older. No&nbsp;clinically relevant differences in safety or efficacy were observed between patients and &ge; 65 years and younger.</p><p>&nbsp;</p><p><strong>To reports any side effect(s): </strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Saudi Arabia</u></strong></p><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;Website: <u>https://ade.</u><strong><u>sfda</u></strong><u>.gov.sa/</u></p><p>&nbsp;</p><p>&nbsp;&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Other GCC States:</u></strong></p><p><em>Please contact the relevant competent authority.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for acalabrutinib overdose and symptoms of overdose have not been established. In the event of an overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EL02.</p><p>&nbsp;</p><p><u><strong>Mechanism of action </strong></u></p><p>Acalabrutinib is a selective inhibitor of Bruton tyrosine kinase (BTK). BTK is a signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signalling results in B-cell survival and proliferation, and is required for cellular adhesion, trafficking, and chemotaxis. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inactivation of BTK with minimal off-target interactions.</p><p>&nbsp;</p><p><strong><u>Pharmacodynamic effects </u></strong></p><p>In patients with B-cell malignancies dosed with acalabrutinib100 mg twice daily, median steady-state BTK occupancy of &ge; 95% in peripheral blood was maintained over 12 hours, resulting in inactivation of BTK throughout the recommended dosing interval.</p><p>&nbsp;</p><p><u><strong>Cardiac electrophysiology </strong></u></p><p>The effect of acalabrutinib on the QTc interval was evaluated in 46 healthy male and female subjects in a randomised, double-blind thorough QT study with placebo and positive controls. At a supratherapeutic dose, 4-times the maximum recommended dose, Acalabrutinib did not prolong the QT/QTc interval to any clinically relevant extent (e.g., not greater than or equal to 10 ms) (see sections 4.4, 4.8 and 5.3).</p><p>&nbsp;</p><p><strong><u>Clinical efficacy and safety </u></strong></p><p>Patients with previously untreated CLL The safety and efficacy of Acalabrutinib in previously untreated CLL were evaluated in a randomised, multi-centre, open-label Phase 3 study (ELEVATE-TN) of 535 patients. Patients received Acalabrutinib plus obinutuzumab, Acalabrutinib monotherapy, or obinutuzumab plus chlorambucil. Patients 65 years of age or older, or between 18 and 65 years of age with coexisting medical conditions, were included in ELEVATE-TN, 27.9% patients had a CrCl of &lt; 60 mL/min. Of the patients who were &lt; 65 years of age, 16.1% had a median CIRS-G score of 8.The study allowed patients to receive antithrombotic agents. Patients who required anticoagulation with warfarin or equivalent vitamin K antagonists were excluded.</p><p>&nbsp;</p><p>Patients were randomised in a 1:1:1 ratio into 3 arms to receive</p><p>&bull; Acalabrutinib plus obinutuzumab (Acalabrutinib +G): Acalabrutinib 100 mg was administered twice daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Obinutuzumab was administered starting on Cycle 2 Day 1 for a maximum of 6 treatment cycles. Obinutuzumab 1,000 mg was administered on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 2 followed by 1,000 mg on Day 1 of Cycles 3 up to 7. Each cycle was 28 days.</p><p>&bull; Acalabrutinib monotherapy: Acalabrutinib 100 mg was administered twice daily until disease progression or unacceptable toxicity.</p><p>&bull; Obinutuzumab plus chlorambucil (GClb): Obinutuzumab and chlorambucil were administered for a maximum of 6 treatment cycles. Obinutuzumab 1,000 mg was administered on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1 followed by 1,000 mg on Day 1 of Cycles 2 up to 6. Chlorambucil 0.5 mg/kg was administered on Days 1 and 15 of Cycles 1 up to 6. Each cycle was 28 days.</p><p>&nbsp;</p><p>Patients were stratified by 17p deletion mutation status (presence versus absence), ECOG performance status (0 or 1 versus 2) and geographic region (North America and Western Europe versus Other). After confirmed disease progression, 45 patients randomised on the GClb arm crossed over to Acalabrutinib monotherapy. Table 5 summarises the baseline demographics and disease characteristics of the study population.</p><p>&nbsp;</p><p>Table 5. Baseline patient characteristics in (ELEVATE-TN) patients with previously untreated CLL</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Characteristic</strong></p></td><td style="vertical-align:top"><p><strong>Acalabrutinib plus obinutuzumab N=179</strong></p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=179</strong></p></td><td style="vertical-align:top"><p><strong>Obinutuzumab plus chlorambucil N=177</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age, years; median (range)</p></td><td style="vertical-align:top"><p>70 (41-88)</p></td><td style="vertical-align:top"><p>70 (44-87)</p></td><td style="vertical-align:top"><p>71 (46-91)</p></td></tr><tr><td style="vertical-align:top"><p>Male; %</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>59.9</p></td></tr><tr><td style="vertical-align:top"><p>Caucasian; %</p></td><td style="vertical-align:top"><p>91.6</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>93.2</p></td></tr><tr><td style="vertical-align:top"><p>ECOG performance status 0-1; %</p></td><td style="vertical-align:top"><p>94.4</p></td><td style="vertical-align:top"><p>92.2</p></td><td style="vertical-align:top"><p>94.4</p></td></tr><tr><td style="vertical-align:top"><p>Median time from diagnosis (months)</p></td><td style="vertical-align:top"><p>30.5</p></td><td style="vertical-align:top"><p>24.4</p></td><td style="vertical-align:top"><p>30.7</p></td></tr><tr><td style="vertical-align:top"><p>Bulky disease with nodes &ge; 5 cm; %</p></td><td style="vertical-align:top"><p>25.7</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>31.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cytogenetics/FISH Category; %</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17p deletion</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>11q deletion</p></td><td style="vertical-align:top"><p>17.3</p></td><td style="vertical-align:top"><p>17.3</p></td><td style="vertical-align:top"><p>18.6</p></td></tr><tr><td style="vertical-align:top"><p>TP53 mutation</p></td><td style="vertical-align:top"><p>11.7</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>11.9</p></td></tr><tr><td style="vertical-align:top"><p>Unmutated IGHV</p></td><td style="vertical-align:top"><p>57.5</p></td><td style="vertical-align:top"><p>66.5</p></td><td style="vertical-align:top"><p>65.5</p></td></tr><tr><td style="vertical-align:top"><p>Complex karyotype (&ge; 3 abnormalities)</p></td><td style="vertical-align:top"><p>16.2</p></td><td style="vertical-align:top"><p>17.3</p></td><td style="vertical-align:top"><p>18.1</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Rai stage; %</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>30.2</p></td><td style="vertical-align:top"><p>26.8</p></td><td style="vertical-align:top"><p>28.2</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:top"><p>20.1</p></td><td style="vertical-align:top"><p>24.6</p></td><td style="vertical-align:top"><p>27.1</p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>26.8</p></td><td style="vertical-align:top"><p>27.9</p></td><td style="vertical-align:top"><p>22.6</p></td></tr><tr><td style="vertical-align:top"><p>IV</p></td><td style="vertical-align:top"><p>21.2</p></td><td style="vertical-align:top"><p>20.7</p></td><td style="vertical-align:top"><p>21.5</p></td></tr></tbody></table><p>The primary endpoint was progression-free survival (PFS) of Acalabrutinib +Garm versus GClb arm as assessed by an Independent Review Committee (IRC) per International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) 2008 criteria with incorporation of the clarification for treatmentrelated lymphocytosis (Cheson 2012). With a median follow-up of 28.3 months, PFS by IRC indicated a 90% statistically significant reduction in the risk of disease progression or death for previously untreated CLL patients in the Acalabrutinib +G arm compared to the GClb arm. Efficacy results are presented inTable 6. The Kaplan-Meier curves for PFS are shown in Figure 1.</p><p>&nbsp;</p><p>Table 6. Efficacy results per IRC Assessments in (ELEVATE-TN) patients with CLL</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Acalabrutinib </strong><strong>plus </strong><strong>obinutuzumab</strong></p><p><strong>N=179</strong></p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=179</strong></p></td><td style="vertical-align:top"><p><strong>Obinutuzumab </strong><strong>plus</strong></p><p><strong>chlorambucil N=177</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression-free survival*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>14 (7.8)</p></td><td style="vertical-align:top"><p>26 (14.5)</p></td><td style="vertical-align:top"><p>93 (52.5)</p></td></tr><tr><td style="vertical-align:top"><p>PD, n (%)</p></td><td style="vertical-align:top"><p>9 (5)</p></td><td style="vertical-align:top"><p>20 (11.2)</p></td><td style="vertical-align:top"><p>82 (46.3)</p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>5 (2.8)</p></td><td style="vertical-align:top"><p>6 (3.4)</p></td><td style="vertical-align:top"><p>11 (6.2)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR (34.2, NR)</p></td><td style="vertical-align:top"><p>22.6 (20.2, 27.6)</p></td></tr><tr><td style="vertical-align:top"><p>HR&dagger; (95% CI)</p></td><td style="vertical-align:top"><p>0.10 (0.06, 0.17)</p></td><td style="vertical-align:top"><p>0.20 (0.13, 0.30)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>24 months estimate,</p><p>% (95% CI)</p></td><td style="vertical-align:top"><p>92.7 (87.4, 95.8)</p></td><td style="vertical-align:top"><p>87.3 (80.9, 91.7)</p></td><td style="vertical-align:top"><p>46.7 (38.5, 54.6)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Overall Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>9 (5)</p></td><td style="vertical-align:top"><p>11 (6.1)</p></td><td style="vertical-align:top"><p>17 (9.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI) &dagger;</p></td><td style="vertical-align:top"><p>0.47 (0.21, 1.06)</p></td><td style="vertical-align:top"><p>0.60 (0.28, 1.27)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Best overall response rate* (CR + CRi + nPR + PR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%) (95% CI)</p></td><td style="vertical-align:top"><p>168 (93.9)</p><p>(89.3, 96.5)</p></td><td style="vertical-align:top"><p>153 (85.5)</p><p>(79.6, 89.9)</p></td><td style="vertical-align:top"><p>139 (78.5)</p><p>(71.9, 83.9)</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>0.0763</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>23 (12.8)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>8 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>CRi, n (%)</p></td><td style="vertical-align:top"><p>1 (0.6) 0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>nPR, n (%)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>3 (1.7)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>143 (79.9)</p></td><td style="vertical-align:top"><p>150 (83.8)</p></td><td style="vertical-align:top"><p>128 (72.3)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>CI=confidence interval; HR=hazard ratio; NR=not reached; CR=complete response; CRi=complete response</p><p>with incomplete blood count recovery; nPR=nodular partial response; PR=partial response;</p><p>*Per IRC assessment</p><p>&dagger;Based on stratified Cox-Proportional-Hazards model</p><p>a Median OS not reached for both arms.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 1. Kaplan-Meier curve of IRC-assessed PFS in (ELEVATE-TN) patients with CLL (ITT Population</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_4" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:160pt;margin-top:7.85pt;width:360.5pt;
  height:207.6pt;z-index:-251654144;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="481" height="277" src="file:///C:/Users/pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="15" style="vertical-align:top"><p>Number of patients at risk</p></td></tr><tr><td style="vertical-align:top"><p>Month</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Acalabrutinib</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>166</p></td><td style="vertical-align:top"><p>161</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>153</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>103</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Acalabrutinib</p><p>+G</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>176</p></td><td style="vertical-align:top"><p>170</p></td><td style="vertical-align:top"><p>168</p></td><td style="vertical-align:top"><p>163</p></td><td style="vertical-align:top"><p>160</p></td><td style="vertical-align:top"><p>159</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>109</p></td><td style="vertical-align:top"><p>104</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>GClb</p></td><td style="vertical-align:top"><p>177</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>157</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>136</p></td><td style="vertical-align:top"><p>113</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>PFS results for Acalabrutinib with or without obinutuzumab were consistent across subgroups, including<br />high risk features. In the high risk CLL population (17p deletion, 11q deletion, TP53 mutation or<br />unmutated IGHV), the PFS HR of Acalabrutinib with or without obinutuzumab versus obinutuzumab<br />plus chlorambucil was 0.08 [95% CI (0.04, 0.15)] and 0.13 [95% CI (0.08, 0.21)], respectively.</p><p>&nbsp;</p><p>Table 7. Subgroup analysis of PFS (Study ELEVATE-TN)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Acalabrutinib monotherapy</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Acalabrutinib + G</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>All subjects</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>0.20</p></td><td style="vertical-align:top"><p>(0.13, 0.30)</p></td><td style="vertical-align:top"><p>179</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>(0.06, 0.17)</p></td></tr><tr><td style="vertical-align:top"><p>Del 17P Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19</p><p>160</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.20</p><p>0.20</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.06, 0.64)</p><p>(0.12, 0.31)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p><p>158</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.13</p><p>0.09</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.04, 0.46)</p><p>(0.05, 0.17)</p></td></tr><tr><td style="vertical-align:top"><p>TP53 mutation Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19</p><p>160</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.15</p><p>0.20</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.05, 0.46)</p><p>(0.12, 0.32)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21</p><p>158</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.04</p><p>0.11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.01, 0.22)</p><p>(0.06, 0.20)</p></td></tr><tr><td style="vertical-align:top"><p>Del 17P or/and TP53 mutation</p><p>Yes No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23</p><p>156</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.23</p><p>0.19</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.09, 0.61)</p><p>(0.11, 0.31)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>25</p><p>154</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.10</p><p>0.10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.03, 0.34)</p><p>(0.05, 0.18)</p></td></tr><tr><td style="vertical-align:top"><p>IGHV mutation Mutated Unmutated</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>58</p><p>119</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.69</p><p>0.11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.31, 1.56)</p><p>(0.07, 0.19)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>74</p><p>103</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.15</p><p>0.08</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.04, 0.52)</p><p>(0.04, 0.16)</p></td></tr><tr><td style="vertical-align:top"><p>Del 11q Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31</p><p>148</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.07</p><p>0.26</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.02, 0.22)</p><p>(0.16, 0.41)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31</p><p>148</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.09</p><p>0.10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.03, 0.26)</p><p>(0.05, 0.20)</p></td></tr><tr><td style="vertical-align:top"><p>Complex Karyotype Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31</p><p>117</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.10</p><p>0.27</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.03, 0.33)</p><p>(0.16, 0.46)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>29</p><p>126</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.09</p><p>0.11</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.03, 0.29)</p><p>(0.05, 0.21)</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients with CLL who received at least one prior therapy</p><p>The safety and efficacy of Acalabrutinib in relapsed or refractory CLL were evaluated in a randomised, multi-centre, open-label phase 3 study (ASCEND) of 310 patients who received at least one prior therapy not including BCL-2 inhibitors or B-cell receptor inhibitors. Patients received Acalabrutinib monotherapy or investigator&rsquo;s choice of either idelalisib plus rituximab or bendamustine plus rituximab. The study allowed patients to receive antithrombotic agents. Patients who required anticoagulation with warfarin or equivalent vitamin K antagonists were excluded.</p><p>Patients were randomized 1:1 to receive either:</p><p>&bull; Acalabrutinib 100 mg twice daily until disease progression or unacceptable toxicity, or &bull; Investigator&rsquo;s choice:</p><p>o Idelalisib 150 mg twice daily in combination with rituximab 375 mg/m2 IV on Day 1 of the first cycle, followed by 500 mg/m2 IV every 2 weeks for 4 doses, then every 4 weeks for 3 doses for a total of 8 infusions</p><p>o Bendamustine 70 mg/m2 (Day 1 and 2 of each 28-day cycle) in combination with rituximab (375 mg/m2/500 mg/m2) on Day 1of each 28-day cycle for up to 6 cycles Patients were stratified by 17p deletion mutation status (presence versus absence), ECOG performance status (0 or 1 versus 2) and number of prior therapies (1 to 3 versus &ge; 4). After confirmed disease progression, 35 patients randomised on investigator&rsquo;s choice of either idelalisib plus rituximab or bendamustine plus rituximab crossed over to Acalabrutinib. Table 8 summarizes the baseline demographics and disease characteristics of the study population.</p><p>&nbsp;</p><p>Table 8. Baseline patient characteristics in (ASCEND) patients with CLL</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Characteristic</strong></p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=155</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&#39;s choice of idelalisib + rituximab or bendamustine + rituximab N=155</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age, years; median (range)</p></td><td style="vertical-align:top"><p>68 (32-89)</p></td><td style="vertical-align:top"><p>67 (34-90)</p></td></tr><tr><td style="vertical-align:top"><p>Male; %</p></td><td style="vertical-align:top"><p>69.7</p></td><td style="vertical-align:top"><p>64.5</p></td></tr><tr><td style="vertical-align:top"><p>Caucasian; %</p></td><td style="vertical-align:top"><p>93.5</p></td><td style="vertical-align:top"><p>91.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>ECOG performance status; %</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>37.4</p></td><td style="vertical-align:top"><p>35.5</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>50.3</p></td><td style="vertical-align:top"><p>51.0</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>12.3</p></td><td style="vertical-align:top"><p>13.5</p></td></tr><tr><td style="vertical-align:top"><p>Median time from diagnosis (months)</p></td><td style="vertical-align:top"><p>85.3</p></td><td style="vertical-align:top"><p>79.0</p></td></tr><tr><td style="vertical-align:top"><p>Bulky disease with nodes &ge; 5 cm; %</p></td><td style="vertical-align:top"><p>49.0</p></td><td style="vertical-align:top"><p>48.4</p></td></tr><tr><td style="vertical-align:top"><p>Median number of prior CLL therapies (range)</p></td><td style="vertical-align:top"><p>1 (1-8)</p></td><td style="vertical-align:top"><p>2 (1-10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of Prior CLL Therapies; %</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>52.9</p></td><td style="vertical-align:top"><p>43.2</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>25.8</p></td><td style="vertical-align:top"><p>29.7</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>11.0</p></td><td style="vertical-align:top"><p>15.5</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 4</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>11.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cytogenetics/FISH Category; %</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17p deletion</p></td><td style="vertical-align:top"><p>18.1</p></td><td style="vertical-align:top"><p>13.5</p></td></tr><tr><td style="vertical-align:top"><p>11q deletion</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>28.4</p></td></tr><tr><td style="vertical-align:top"><p>TP53 mutation</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>21.9</p></td></tr><tr><td style="vertical-align:top"><p>Unmutated IGHV</p></td><td style="vertical-align:top"><p>76.1</p></td><td style="vertical-align:top"><p>80.6</p></td></tr><tr><td style="vertical-align:top"><p>Complex karyotype (&ge;3 abnormalities)</p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top"><p>29.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Rai Stage; %</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>25.2</p></td><td style="vertical-align:top"><p>20.6</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:top"><p>31.6</p></td><td style="vertical-align:top"><p>34.8</p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>11.6</p></td></tr><tr><td style="vertical-align:top"><p>IV</p></td><td style="vertical-align:top"><p>28.4</p></td><td style="vertical-align:top"><p>29.7</p></td></tr></tbody></table><p>The primary endpoint was PFS as assessed by IRC IWCLL 2008 criteria with incorporation of the<br />clarification for treatment-related lymphocytosis (Cheson 2012). With a median follow-up of<br />16.1months, PFS indicated a 69% statistically significant reduction in the risk of death or progression<br />for patients in the Acalabrutinib arm. Efficacy results are presented in Table 9. The Kaplan-Meier curve<br />for PFS is shown in Figure 2.</p><p>&nbsp;</p><p>Table 9. Efficacy results per IRC Assessments in (ASCEND) patients with CLL</p><table border="1" cellspacing="0" cellpadding="0" style="width:592px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=155</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Progression-free survival*</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>27 (17.4)</p></td><td colspan="2" style="vertical-align:top"><p>68 (43.9)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>PD, n (%)</p></td><td style="vertical-align:top"><p>19 (12.3)</p></td><td colspan="2" style="vertical-align:top"><p>59 (38.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>8 (5.2)</p></td><td colspan="2" style="vertical-align:top"><p>9 (5.8)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td colspan="2" style="vertical-align:top"><p>16.5 (14.0, 17.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>HR&dagger; (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.31 (0.20, 0.49)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>P-value</p></td><td colspan="3" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>15 months estimate, % (95% CI)</p></td><td style="vertical-align:top"><p>82.6 (75.0, 88.1)</p></td><td colspan="2" style="vertical-align:top"><p>54.9 (45.4, 63.5)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Overall survivala</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>15 (9.7)</p></td><td colspan="2" style="vertical-align:top"><p>18(11.6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard Ratio (95% CI) &dagger;</p></td><td style="vertical-align:top"><p>0.84 (0.42, 1.66)</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Best overall response rate* (CR + CRi + nPR + PR)**</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ORR, n (%) (95% CI)</p></td><td style="vertical-align:top"><p>126 (81.3)</p><p>(74.4, 86.6)</p></td><td colspan="2" style="vertical-align:top"><p>117 (75.5)</p><p>(68.1, 81.6)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>0.2248</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>2 (1.3)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>126 (81.3)</p></td><td colspan="2" style="vertical-align:top"><p>115 (74.2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Duration of Response (Dor)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td colspan="3" style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>13.6 (11.9,NR)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=155</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>CI=confidence interval; HR=hazard ratio; NR=not reached; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response; PD=progressive disease</p><p>*Per IRC assessment</p><p>a Median OS not reached for both arms. P&lt;0.6089 for OS.</p><p>**CRi and nPR have values of 0.</p><p>&dagger;Based on stratified Cox-Proportional-Hazards model</p></td></tr></tbody></table><p>&nbsp;</p><p>With long term data, the median follow-up was 22.1 months for Acalabrutinib and 21.9 months for the<br />IR/BR. The median PFS was not reached in Acalabrutinib and was 16.8 months in IR/BR. The<br />hazard ratio of INV-assessed PFS of Acalabrutinib compared with IR/BR was 0.27 [95% CI,<br />0.18 to 0.40] representing a 73% reduction in the risk of death or progression for patients in the<br />Acalabrutinib arm. Efficacy results per Investigator Assessments (INV) are presented in Table<br />10.</p><p>&nbsp;</p><p>Table 10. Long term follow-up efficacy results per INV assessments in(ASCEND) patients with CLL</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=155</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-free survival*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>35 (22.6)</p></td><td style="vertical-align:top"><p>90 (58.1)</p></td></tr><tr><td style="vertical-align:top"><p>PD, n (%)</p></td><td style="vertical-align:top"><p>23 (14.8)</p></td><td style="vertical-align:top"><p>79 (51)</p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>12 (7.7)</p></td><td style="vertical-align:top"><p>11 (7.1)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>16.8 (14.1, 22.4)</p></td></tr><tr><td style="vertical-align:top"><p>HR&dagger; (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.27 (0.18, 0.40)</p></td></tr><tr><td style="vertical-align:top"><p>21 months estimate, % (95% CI)</p></td><td style="vertical-align:top"><p>79.1 (71.5, 84.8)</p></td><td style="vertical-align:top"><p>45.3 (36.9, 53.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survivala</strong></p></td></tr><tr><td style="vertical-align:top"><p>Death events (%)</p></td><td style="vertical-align:top"><p>21 (13.5)</p></td><td style="vertical-align:top"><p>26 (16.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI) &dagger;</p></td><td style="vertical-align:top"><p>0.78 (0.44, 1.40)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Best overall response rate* (CR + CRi + nPR + PR)**</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%)</p></td><td style="vertical-align:top"><p>124 (80)</p></td><td style="vertical-align:top"><p>130 (83.9)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(73, 85.5)</p></td><td style="vertical-align:top"><p>(77.3, 88.8)</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td style="vertical-align:top"><p>0.3516</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>5 (3.2)</p></td><td style="vertical-align:top"><p>6 (3.9)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>114 (73.5)</p></td><td style="vertical-align:top"><p>122 (78.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;Duration of Response (Dor)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>18 (11.9, 19.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Acalabrutinib monotherapy N=155</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&rsquo;s choice of idelalisib + rituximab or bendamustine + rituximab</strong></p><p><strong>N=155</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI=confidence interval; HR=hazard ratio; NR=not reached; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response; PD=progressive disease</p><p>*Per INV assessment</p><p>a Median OS not reached for both arms P&lt;0.4094 for OS.</p><p>**CRi and nPR have values of 2 and 5.</p><p>&nbsp; &dagger;Based on stratified Cox-Proportional-Hazards model</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure 2. Kaplan-Meier curve of IRC-assessed PFS in (ASCEND) patients with CLL(ITT Population)</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_5" o:spid="_x0000_s1026" type="#_x0000_t75"
  alt="A graph of a number of patients&#10;&#10;Description automatically generated with medium confidence"
  style='position:absolute;margin-left:143pt;margin-top:7.15pt;width:355.45pt;
  height:157.1pt;z-index:-251652096;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title="A graph of a number of patients&#10;&#10;Description automatically generated with medium confidence"/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="474" height="209" alt="A graph of a number of patients

Description automatically generated with medium confidence" src="file:///C:/Users/pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="25" style="vertical-align:top"><p>Number of patients at risk</p></td></tr><tr><td style="vertical-align:top"><p>Month</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>2</p><p>1</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>23</p></td></tr><tr><td style="vertical-align:top"><p>Acalabrutinib</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>15</p><p>3</p></td><td style="vertical-align:top"><p>15</p><p>3</p></td><td style="vertical-align:top"><p>14</p><p>9</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>14</p><p>6</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>143</p></td><td style="vertical-align:top"><p>143</p></td><td style="vertical-align:top"><p>139</p></td><td style="vertical-align:top"><p>139</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>118</p></td><td style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Investigator&#39;s Choice</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>15</p><p>0</p></td><td style="vertical-align:top"><p>15</p><p>0</p></td><td style="vertical-align:top"><p>14</p><p>6</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>14</p><p>2</p></td><td style="vertical-align:top"><p>136</p></td><td style="vertical-align:top"><p>130</p></td><td style="vertical-align:top"><p>129</p></td><td style="vertical-align:top"><p>112</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>101</p></td><td style="vertical-align:top"><p>82</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Table 11. Subgroup analysis of PFS (Study ASCEND)</p><table border="1" cellspacing="0" cellpadding="0" style="width:588px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Acalabrutinib monotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>All subjects</p></td><td style="vertical-align:top"><p>155</p></td><td style="vertical-align:top"><p>0.27</p></td><td style="vertical-align:top"><p>(0.18, 0.40)</p></td></tr><tr><td style="vertical-align:top"><p>Del 17P Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>28</p><p>127</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.18</p><p>0.30</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.07, 0.43)</p><p>(0.19, 0.47)</p></td></tr><tr><td style="vertical-align:top"><p>TP53 mutation Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39</p><p>113</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.17</p><p>0.33</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.08, 0.37)</p><p>(0.21, 0.52)</p></td></tr><tr><td style="vertical-align:top"><p>Del 17P or TP53 mutation</p><p>Yes No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>45</p><p>108</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.16</p><p>0.34</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.08, 0.34)</p><p>(0.22, 0.55)</p></td></tr><tr><td style="vertical-align:top"><p>IGHV mutation</p><p>Mutated Unmutated</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>33</p><p>118</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.30</p><p>0.28</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.12, 0.76)</p><p>(0.18, 0.43)</p></td></tr><tr><td style="vertical-align:top"><p>Del 11q Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39</p><p>116</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.35</p><p>0.26</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.16, 0.75)</p><p>(0.16, 0.41)</p></td></tr><tr><td style="vertical-align:top"><p>Complex Karyotype Yes</p><p>No</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>50</p><p>97</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.28</p><p>0.25</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>(0.15, 0.53)</p><p>(0.15, 0.44)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics (PK) of acalabrutinib and its active metabolite, ACP-5862, were studied in healthy subjects and in patients with B-cell malignancies. Acalabrutinib exhibits dose-proportionality, and both acalabrutinib and ACP-5862 exhibit almost linear PK across a dose range of 75 to 250 mg. Population PK modelling suggests that the PK of acalabrutinib and ACP-5862 is similar across patients with different B-cell malignancies. At the recommended dose of 100 mg twice daily in patients with Bcell malignancies (including, CLL), the geometric mean steady state daily area under the plasma concentration over time curve (AUC24h) and maximum plasma concentration (Cmax) for acalabrutinib were 1679 ng&bull;h/mL and 438 ng/mL, respectively, and for ACP-5862 were 4166 ng&bull;h/mL and 446 ng/mL, respectively.</p><p>&nbsp;</p><p><u><strong>Absorption </strong></u></p><p>The time to peak plasma concentrations (Tmax) was 0.5-1.5hours for acalabrutinib, and 1.0 hour for ACP5862. The absolute bioavailability of Acalabrutinib was 25%. Effect of food on acalabrutinib In healthy subjects, administration of a single 75 mg dose of acalabrutinib with a high fat, high calorie meal (approximately 918 calories, 59 grams carbohydrate, 59 grams fat and 39 grams protein) did not affect the mean AUC as compared to dosing under fasted conditions. Resulting Cmax decreased by 69% and Tmax was delayed 1-2 hours.</p><p>&nbsp;</p><p><u><strong>Distribution </strong></u></p><p>Reversible binding to human plasma protein was 99.4% for acalabrutinib and 98.8% for ACP- 5862. The in vitro mean blood-to-plasma ratio was 0.8 for acalabrutinib and 0.7 for ACP- 5862. The mean steady state volume of distribution (Vss) was approximately 34 L for acalabrutinib.</p><p>&nbsp;</p><p><u><strong>Biotransformation/Metabolism </strong></u></p><p>In vitro, acalabrutinib is predominantly metabolised by CYP3A enzymes, and to a minor extent by glutathione conjugation and amide hydrolysis. ACP-5862 was identified as the major metabolite in plasma, that was further metabolized primarily by CYP3A-mediated oxidation, with a geometric mean exposure (AUC) that was approximately 2- to 3-fold higher than the exposure of acalabrutinib. ACP5862 is approximately 50% less potent than acalabrutinib with regard to BTK inhibition.</p><p>In vitro studies indicate that acalabrutinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, UGT1A1 or UGT2B7 at clinically relevant concentrations and is unlikely to affect clearance of substrates of these CYPs.</p><p>In vitro studies indicate that ACP-5862 does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, UGT1A1 or UGT2B7 at clinically relevant concentrations and is unlikely to affect clearance of substrates of these CYPs.</p><p>&nbsp;</p><p><strong><u>Interactions with transport proteins </u></strong></p><p>In vitro studies indicate that acalabrutinib and ACP-5862 are P-gp and BCRP substrates. Coadministration with BCRP inhibitors is however unlikely to result in clinically relevant drug interactions. Co-administration with an OATP1B1/1B3 inhibitor (600 mg rifampin, single dose) resulted in an increase in acalabrutinib Cmax and AUC by 1.2-fold and 1.4-fold (N=24, healthy subjects), respectively, which is not clinically relevant.</p><p>Acalabrutinib and ACP-5862 do not inhibit P-gp, OAT1, OAT3, OCT2, OATP1B1, OATP1B3 and MATE2-K at clinically relevant concentrations. Acalabrutinib may inhibit intestinal BCRP, while ACP5862 may inhibit MATE1 at clinically relevant concentrations (see section 4.5). Acalabrutinib does not inhibit MATE1, while ACP-5862 does not inhibit BCRP at clinically relevant concentrations.</p><p>&nbsp;</p><p><u><strong>Elimination</strong></u></p><p>Following a single oral dose of 100 mg acalabrutinib, the terminal elimination half-life (t1/2) of acalabrutinib was) 1 to 2 hours. The t1/2 of the active metabolite, ACP-5862, was approximately 7 hours</p><p>The mean apparent oral clearance (CL/F) was 134 L/hr for acalabrutinib and 22 L/hr for ACP-5862 in patients with B-cell malignancies.</p><p>Following administration of a single 100 mg radiolabelled [14C]-acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the faeces and 12% of the dose was recovered in the urine, with less than 2% of the dose excreted as unchanged acalabrutinib.</p><p>&nbsp;</p><p><strong><u>Special populations</u></strong></p><p>Based on population PK analysis, age (&gt;18 years of age), sex, race (Caucasian, African American) and body weight did not have clinically meaningful effects on the PK of acalabrutinib and its active metabolite, ACP-5862</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>No pharmacokinetic studies were performed with Acalabrutinib in patients under 18 years of age.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Acalabrutinib undergoes minimal renal elimination. A pharmacokinetic study in patients with renal impairment has not been conducted. Based on population PK analysis, no clinically relevant PK difference was observed in 408 subjects with mild renal impairment (eGFR between 60 and 89 mL/min/1.73m2 as estimated by MDRD), 109 subjects with moderate renal impairment (eGFR between 30 and 59 mL/min/1.73m2) relative to 192 subjects with normal renal function (eGFR greater than or equal to 90 mL/min/1.73m2). The pharmacokinetics of acalabrutinib has not been characterised in patients with severe renal impairment (eGFR less than 29 mL/min/1.73m2) or renal impairment requiring dialysis. Patients with creatinine levels greater than 2.5 times the institutional ULN were not included in the clinical studies (see section 4.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>Acalabrutinib is metabolised in the liver. In dedicated hepatic impairment (HI) studies, compared to subjects with normal liver function (n=6), acalabrutinib exposure (AUC) was increased by 1.9-fold, 1.5- fold and 5.3-fold in subjects with mild (n=6) (Child-Pugh A), moderate (n=6) (Child-Pugh B) and severe (n=8) (Child-Pugh C) hepatic impairment, respectively. Subjects in the moderate HI group were however not significantly affected in markers relevant for the elimination capacity of drugs, so the effect of moderate hepatic impairment was likely underestimated in this study. Based on a population PK analysis, no clinically relevant difference was observed between subjects with mild (n=79) or moderate (n=6) hepatic impairment (total bilirubin between 1.5 to 3 times ULN and any AST) relative to subjects with normal (n=613) hepatic function (total bilirubin and AST within ULN) (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Carcinogenicity </strong></u></p><p>Carcinogenicity studies have not been conducted with acalabrutinib.</p><p>&nbsp;</p><p><u><strong>Genotoxicity/Mutagenicity/Phototoxicity </strong></u></p><p>Acalabrutinib was not mutagenic in a bacterial reverse mutation assay, in an in vitro chromosome aberration assay or in an in vivo mouse bone marrow micronucleus assay. Acalabrutinib was found to have a possible phototoxic potential in an in vitro phototoxicity assay using 3T3 cell line (see section 4.4).</p><p>&nbsp;</p><p><u><strong>Repeat-dose toxicity </strong></u></p><p>In rats, microscopic findings of minimal to mild severity were observed in the pancreas (hemorrhage/pigment/inflammation/ fibrosis in islets) at all dose levels. Non-adverse findings of minimal to mild severity in the kidneys (tubular basophilia, tubular regeneration, and inflammation) were observed in studies of up to 6-month duration with a No Observed Adverse Effect level (NOAEL) of 30 mg/kg/day in rats. The mean exposures (AUC) at the NOAEL in male and female rats correspond to 0.6x and 1x, respectively, the clinical exposure at the recommended dose of 100 mg twice daily, respectively. The Lowest Adverse Observed Effect Level (LOAEL) at which reversible renal (moderate tubular degeneration) and liver (individual hepatocyte necrosis) findings were observed in the chronic rat study was 100 mg/kg/day and provided an exposure margin 4.2 times greater than the clinical exposure at the recommended dose of 100 mg twice daily. In studies of 9 months duration in dogs, the NOAEL was 10 mg/kg/day corresponding to an exposure 3x the clinical AUC at the recommended clinical dose. Minimal tubular degeneration in kidney, slight decreases in spleen weights and transient minimal to mild decreases in red cell mass and increases in ALT and ALP were observed at 30 mg/kg/day (9x the clinical AUC) in dogs. Cardiac toxicities in rats (myocardial haemorrhage, inflammation, necrosis) and dogs (perivascular/vascular inflammation) were observed only in animals that died during studies at doses above the maximum tolerated dose (MTD). The exposures in rats and dogs with cardiac findings was at least 6.8 times and 25 times the clinical AUC, respectively. Reversibility for the heart findings could not be assessed as these findings were only observed at doses above the MTD.</p><p>&nbsp;</p><p><u><strong>Reproductive toxicology </strong></u></p><p>No effects on fertility were observed in male or female rats at exposures 10 or 9 times the clinical AUC at the recommended dose, respectively.</p><p>No effects on embryofoetal development and survival were observed in pregnant rats, at exposures&nbsp;approximately 9 times the AUC in patients at the recommended dose of 100 mg twice daily. In two rat reproductive studies, dystocia (prolonged/difficult labour) was observed at exposures &gt;2.3 times the clinical exposure at 100mg twice daily. The presence of acalabrutinib and its active metabolite were confirmed in foetal rat plasma. Acalabrutinib and its active metabolite were present in the milk of lactating rats.</p><p>In an embryofoetal study in pregnant rabbits, decreased foetal body weight and delayed ossification were observed at exposure levels that produced maternal toxicity which were 2.4 times greater than the human AUC at the recommended dose.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content </u></p><p>Mannitol</p><p>Croscarmellose sodium</p><p>Colloidal silicon dioxide</p><p>Sodium stearyl fumarate</p><p>&nbsp;</p><p><u>Capsule shell </u></p><p>Gelatin</p><p>Titanium dioxide (E171)</p><p>FD &amp; C Blue 2</p><p>Iron oxide yellow (E172)</p><p>Purified Water</p><p>&nbsp;</p><p><u>Printing ink </u></p><p>Shellac</p><p>Dehydrated Alcohol</p><p>Isopropyl Alcohol</p><p>Butyl Alcohol</p><p>Propylene glycol (E1520)</p><p>Strong Ammonia Solution</p><p>Black iron oxide (E172)</p><p>Potassium Hydroxide</p><p>Purified Water</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p><p>Store in the original blister to protect from moisture.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acalabrutinib BOS is hard gelatin capsule size &lsquo;1&rsquo; with dark blue opaque color cap and yellow opaque body and printed with &ldquo;NAT 100 mg&rdquo; on body in black ink.</p><p>Acalabrutinib BOS capsules are packed in blisters. Each blister pack contains 60 hard-gelatin capsules.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boston Oncology Arabia
Sudair Industrial City,
Sudair, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>